var title_f5_30_5600="Diameters of the vertex brow and face presentation";
var content_f5_30_5600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Diameters of the vertex, brow, and face presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Vertex presentation with widest diameter suboccipitobregmatic, mean length 11.9 cm.",
"    <br>",
"     (B) Brow presentation with widest diameter mentoparietal, mean length 13.4 cm.",
"     <br>",
"      (C) Face presentation with widest diameter trachelobregmatic or trachelpariaetal, mean length 12.6.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Data from: Borell, U, Fernstrom, I. The mechanism of labour in face and brow presentation. Acta Obst et Gynec Scandinav 1960; 39:626.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5600=[""].join("\n");
var outline_f5_30_5600=null;
var title_f5_30_5601="Partial nail avulsion";
var content_f5_30_5601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Removal of a lateral wedge of toenail in a partial avulsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Krull, EA. Surgery of the nail. In: Dermatology, 3rd ed, Moschella, SL, Hurley, HJ (Eds), WB Saunders, Philadelphia 1992. p.2407. Reproduced with permission from Atlas of Office Procedures 1999; 2:97. Copyright 1999 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5601=[""].join("\n");
var outline_f5_30_5601=null;
var title_f5_30_5602="Patient information: Familial hypercholesterolemia (The Basics)";
var content_f5_30_5602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83337\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"         Heart attack symptoms",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21542\">",
"          Signs of stroke",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Familial hypercholesterolemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/familial-hypercholesterolemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9335631\">",
"      <span class=\"h1\">",
"       What is familial hypercholesterolemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Familial hypercholesterolemia is a disorder that causes too much cholesterol and fat to build up in the body. When the cholesterol and fat build up inside the arteries in the heart, they can cause heart attacks. As a result, people with this disorder can have heart attacks at a very young age&mdash;sometimes even as children.",
"     </p>",
"     <p>",
"      Familial hypercholesterolemia, often called &ldquo;FH,&rdquo; is passed on in families. There are 2 main forms of the condition:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Heterozygous FH",
"        </strong>",
"        &ndash; In this form, a child gets the FH gene from just 1 parent.",
"       </li>",
"       <li>",
"        <strong>",
"         Homozygous FH",
"        </strong>",
"        &ndash; In this form, a child gets the FH gene from both parents. This form of FH is much more severe than the other. People with homozygous FH have very high levels of cholesterol. They have a very high risk of having heart attacks and dying young.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9335646\">",
"      <span class=\"h1\">",
"       What are the symptoms of FH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most serious symptom of FH is a heart attack. But thanks to medicines, the rates of heart attacks in people with FH have dropped.",
"     </p>",
"     <p>",
"      FH can also cause firm, fatty deposits to form under the skin. These deposits are called &ldquo;xanthomas.&rdquo; They can form on different parts of the body, such as at the heel of the foot, around the knee or elbow, and around the eyes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9335669\">",
"      <span class=\"h1\">",
"       Is there a test for FH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Routine blood tests to measure cholesterol can show whether a person&rsquo;s cholesterol levels are unusually high. If so, the doctor or nurse can look further for a possible cause and can then find out if FH is the problem.",
"     </p>",
"     <p>",
"      Children should have routine cholesterol tests once around age 9 to 12 and again around age 17 to 21. Some children get tested younger if they have a parent with FH or if they show signs of FH, such as xanthomas.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9335684\">",
"      <span class=\"h1\">",
"       How is FH treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;FH is usually treated with medicines called statins, which lower cholesterol. Some people also get other medicines to lower cholesterol. Plus, people with the most severe forms of FH need other special treatments.",
"     </p>",
"     <p>",
"      If you have FH, it&rsquo;s very important that you take your medicines every day as directed. If the medicines cause any problems, or if you cannot afford your medicines, talk to your doctor or nurse. He or she might have possible solutions for you to try. The medicines used to treat FH can keep you from having a heart attack and help you live longer.",
"     </p>",
"     <p>",
"      It&rsquo;s also important that you limit the amount of meat and fried foods you eat. The body converts these and other fatty foods into cholesterol, so you should avoid them if possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9335699\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Make sure you talk to your doctor before you start trying to get pregnant. He or she will need to check the condition of your heart to make sure pregnancy is safe. Plus, you will need to stop taking your FH medicines for at least 3 months before you start trying to get pregnant. That&rsquo;s because the medicines used to treat FH, including statins, can harm a baby. You should not take your FH medicines while you are pregnant or breastfeeding.",
"     </p>",
"     <p>",
"      Be aware that there is a good chance you will pass on your disorder to your baby. Before you start trying to get pregnant, you and your partner should meet with your doctor to learn about the possible risks to your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9335813\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you stay on your medicines, eat right, and do all the things your doctor recommends, you will greatly reduce your chances of having a heart attack. Even so, be aware that you have a high risk of heart attacks and strokes, so you should learn to recognize their symptoms (",
"      <a class=\"graphic graphic_figure graphicRef52579 \" href=\"UTD.htm?1/15/1268\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73487 \" href=\"UTD.htm?21/2/21542\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9335714\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/30/5602?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83337 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5602=[""].join("\n");
var outline_f5_30_5602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335631\">",
"      What is familial hypercholesterolemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335646\">",
"      What are the symptoms of FH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335669\">",
"      Is there a test for FH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335684\">",
"      How is FH treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335699\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335813\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9335714\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"      Heart attack symptoms",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21542\">",
"       Signs of stroke",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_30_5603="Malignant mesothelioma EM";
var content_f5_30_5603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 245px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD1AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDOtbh/PnjUsrDrxkDPvWpBab5yzO5PBP5VyGnatPFbPIU3gtnjjt/9aus0y9SW0Wc5Ct827p7VU4uLOGLTLBtUhnRiSwz1LfdrQIc4KEcDrj9azreVbhmUfOAcBgeBVmaObYPLkz9anW5RCzslwoQgsBkkH8/pUsenabcqZp7S1lYnO9ox1/zis7yHe9WTzA0A4ZM9R/nNTQTJBI0cKllZz0/lWln3ITK2oXehWMvkHT4GdcbljhU7fc8fSuc1V/Dd4GaC3nhnPJNoQqn/AICeKfcbrXXr0XkeyKWQyRliV3LjsfwxVG4ngYhEEcWQOerZz14rqhTS1RlKbejILbRfDs0wW+bVoc5DPI6svTpkVoaj8NFuIo7jQbsOpAYJcHOR9R/WqkFnqF7KY47Scoy4MjrgH8TVjXZ76C4sbOSWWKBYd4CnG88g59hihpt+7IFLTVHOXOh6jo9xtvbSWDAOJYsspx/tL0q5/bbSaZFpupTeZaI++G5QDfGw9x16nr1rrvA+u26iSz1CYGLuJBkA/risv4j+GLWKEalpBX7Ox2uIzlc56U1N83LNByq3MmXNM8O/2h5DR3D31sV65Eaqw/vAda6XTxqUDSQQWzSsh3eaG24/2QPavMfD2t3nh25WWzcva4AeNznj1H9K9m8J61b63YCdWAkGPMH8Sn6Vz4j2kdXqjWlyy23LK3ckgRnZTO3G3OAPWs/x5ayT6VFdJIiSW5D9M/KeD/j+FaUdin2xpxE+7lVJ7j1NP1iNbiB4Y0DuQyEM+Bz/AD+lctOXLNNG8leNmeJ3lwuw+e5IBwHAwzc1mpqLWeoLdQOEYLtbHIPPQ+/vWn4m0q5sdRMZ2uxGM9QQORWBk/ZneEIJ4uQr9CfU/wD1q9hO6PPtZnXQa0txcxZMauPvMo2k/wCP/wCumpD9puybLLOw4RiCeOcA1yNvM9uyLIiSj72wHgZHJH+FdBo16kTxzKoVgec8D361L20H11Oh06eW4tEO+NJIiSI8cluh/DpXd6JfSahZqs6FZYG+YEc1zGq6SWMF7psm4PhxlvXuc1t6JfCwYm/UfaF+Vs9HyeK4K7543juddH3ZWexuS6PLcMHjiKrjO4nGOORVSHw8ft3mXd087YwkYBCn23HmuqsLjzrZGflyNxC4OKi1NtgUKA0jthc9cVwKtNaXOx0oPWxhfa5YZVa3kdJhgssceRjpt961rDULqONBLHsdSGcbgwbPdT/SprO0LGMuQyKcqVGP/wBdLqNptkWdXIdT90fxc+nf6VMp82hUYW1NezvkuCGVgRjJBParbBZQCGdcHOVrmbYlrQiPzILgkjnpu9DWhaPKEiVshicEj5SKxehqtSa5huWkVWZkj9U5J/wqpHYOXZwu+RSRukfoK2lfBGWyPpSvJEMjGSOtLmY7ITTlljjPnBQT6HIxU13JI6bY8g565xio4rhJGCxAkkZ54p6RllIZgW7jrmk5MLIu2mQoAkbIHODnNWkdhyMt2GG/SsaC0XCGP9245O0nB+tWoyZg0fmsJFHHHH1ppsLGgMv/AKwAg8genp+NIMQx8Hco7sckf54qGBCrITMzE5OSev6e36VYkVZFKEjHfnj8v89Keoi1G+SpBzgdRVuOViQACBWUvmRsFUAqT3GM1bgZ+Ny459c1akJoukK/BzlvQ4JxT402YALFfc1Fu2AEngnGcYp/nAc4JA5J9K0TXUz1ILZAL6fbuGMZPXJI9aWbal/bsxIJDKMfSmC8jU7VLAnpkd++e/402ZM3MLBjhTj6Ej/9dK/Yqxoqcd8/0qOeNZDllzjnpVFn+xNhFclsk9wTn9KtQ3HmKpKOjnqrLitVLm0IasUb6Cd3UxMETvz37ZHeitJ2HQnB6AZop2Fc+K4ZFgdYYEDOy/MWHWuw0csLVEdVUkY2KOlcRpTE6nHLL86n36V3tkVih3kdDwT/APXrurLZI8+DHwQC1uD5MRw3LDuPpWkNyp90njuO9cc/iqaaaSLToFKoSpeUnr7CpYfFN9EwLw2kinI4ZlJ/mKn2E9x+0iLrV61hffuWdJyMhT0f396m0TX7eZhDdr9kmPCsTuQt7HsfY1JevYeJrVFSVbbUYv8AVLJwQfT3BrkL8MsjQPCYnBw6Ecj/AOt710RgpqzWplKTi7o9Ov8AT21HSpIbwIxXOCw3Y965y01NLA4tNNhdoz8zrGOcehHTvU/gzXFliGm30g87GyF8/eX+7/vD9ar3uny6ZdzqY7h4ZWLRtECwb/ZOO/4VlGFm4SLcr2kjr9PuItStUvLZ3Xd8rLjlT3X86qNoguiZL6KKbGQFbOQM54PrWFoV9JokF1JdRmO3kYuqlTkHpj+VWj4zEcmJLGXys4LDj8aSpTTfJsVzxt725zOvaNbWGtIsMTw+aSdgBbPHT86ozf6KtyscLxecPKK4wu49Tius8Uappeq2EM4uhb3MTb4ZSNwz6MBzj/CuSMk99eQtxeRjDOF3KpA/2iM/pXXC/L7xzytfQoXGn3On3Gy7QKjICg2gdexqfw/rMvh3VjcRQM9s42vGDgdetdxJqGneI3j0vW7F7Q4AhmWTIB7DPGPxrB8U+E7/AE60l+zlr2yA3b1T51x2Yd/qKnnjL3KmjK5Wveidpb/EHQGjB+2uMj7rRkEHuDWtY3dn4hsWnsZklXO0MDjHPQ+leI6VDbzHDTAKoxn+gFWYbjU9JivnsFaCCVRDNOe244BAHAI5/Os5YSK+FlxxEuqN3xpr+lrp93ZfZ5H1GLciMnzDPu36muB06EvAFdMIwzxwW49f8ir+nabcXt9HYWcJupmDEqoBOR3POPxq6ls+nXr2txC0UqHYysoJ/L8fWuiMFH3UzKUm1dlOw0S9O27SFRA6b0Zuhx1Az3HNXVWQGVRFs2LuK9Cxz27V2GmSRx6AlpIVSS1uklRMAZjk6j860Naskl1K2KeXFcGRVIwAFD8A49s1n7Szsy+S6ujlrHVrm0t4luGUJgEH7ytz3HbtzXW2VjqV5DGz25nV0+RlcNgnkdOo+tZ2q6ZLpzQ204R0bKkKcENjkj24qrax3VhIkdhdzRbDk5J2Y6g57VnNc6vEqL5XaR6h4e0+e2jdpYvJyNqqX3Y+uOn0qbUHkWYLKFIXGzjqO/41xGm+NdRgkb7XGJoVPVUIK+9drpuradrtjxImQAWXdgrXm1aE4O8jvp1YSVkOW8u0crFE7jOMkgAZ56dquSmY3cUbEOhOWPpSRWtsqMfNyp54Ycfl1rRh8i4UEFZNvGe4rnaubp2KxscOJYiRKB07N9aS0kkjlb7ZGVGAQSMj86txtl8IjF156YB/GpnQOoLA7wOg61PKO5WF2jlRHJuUsRyM1XS3nN+ZfOVkJygKjOPxqPWY7TT7SSaRhbxn7zhguDmsK28R2kV6NmpQoqqDvlZWB9R61SpSkrpCc4p2Z28CvFF87Lj1qyijk/db1HeuXfxTpcKNE14jyBd6qgJLemKrHxJK9pJ/oc7KD1Y4YHvwB6ZqVh5dg9rE7JRgAIxGDmrcSgDJPQfj61w1rrdxJFAIY0cMcrltpfjp0/OtKI3d0C9/M8cJGTDbnYo9Mt1NDhy/ENT5tjop54rYsXMaxgcM7AZP1NRR6jbrhkLyu2eIVJB9KytO0qCOYTSRs+MndI27Pp19K10YAHao5OQBS22H6kkN3PJ8y22EznEj7T+GM4/GraX1wrKrWpUMOvmZ/pVOK5iErCMksMDk8c1eSRgVDMGPtzn3oQaE322TcFNlOw7nK4/nUtrO4GGt2AYZKhske1MhbO5WIHPbrU0mx1KtnOB8wHT3zV2ZOmxTF7FcSkqoVx1U9QM96s6gu2OEJhWeVAxP15OawnZrbUQywnDHDZAOOeB/9euiknSS23gF02k4x6UJdRvsWZ0XycsN23nOMn8PWmuZFYBQMHjBPQ1RsLi7mgQloUGN3IJbn8f51aifC5kIY9z2rRLsQx7q28FslPTHTjrRT2AcYQgeuPSitVEi58VzrFaavKkUcssUfyyLEfu9+/U1taZqiCN41laSFiyxljhl46YNZd8kunXM8xUzQSneJAp+Vscqf8ab4eEN9cXNxEh8pWTzFPdsnPU56V6bSauzzE9bGZHZ3Yu9pZwr52gDoPr1rpbGz0u6j+z3IuLO5OB5gfcrN25PHPpxWtf+HVmhE9iwDAbvKY8MPQHt+tZC3MPlG2uYgHUYdZFAYHOef8afN7Re6Ll5dyrPYmG9ubS5BJiAcSKPlKk/eHpWxofk6wX0zU289kBa3nBAkQf3c+vOa5+X7ZcOI4W8wwIZIvXaPvJz29Kh0nU/K1e2uUSRo1J3kKMgEc/iKuUHKOm5Kkk/I6K98E3kYJtbmK4ixnDjY3t07/lWda61qGiytEZpRLHgvBPk5+hqaTVro31y1tqU7ZJlhKv8rKehAP5Ee1bljPp/iiIWesQxx3wXMcicFhjqp9fap1S99XQ9G/d0C51Wx8V6asUUq2+oIRIsMzYDe2fQ+tZ8+lalLZmNbKRJOhDHOT7Y/nVHX/CF3YRu0MDXsCnKPGBvQepX/CotM8Q6nBCiWN83lpwRcYfHtk8inGLt+7YNq/vlm38Jaw7iVbRFO4MC7befp9OKupoeq6Y6u9pmIOWYwDcQvpx1pkXjHXRGdyWmA2N3ltzVK98V6vcOYpbwwopOVgTYWPpu6gU1Gq/isK9NbBq2obrZ4Wga2ZpMmSVCgAyOT+Xua3rnx78jx6JZGYomTJL8it7gdTXBSyCbUfkM95cFvk3EyEH8f51BfPfw3Xk74UuQSzBWzsz2J6fhVujFtXEqklsTXy3V/qX22dIRKMExQrtDev4132o3FpqHhXy4LUQO8Hmox4GQMkk+vFcb4TsoZNWWLXbiSIFWc7SoQqvJDHqBWp418WW2pQJpuiYSzQbXcDG8dgPaplHmkklsNO0W2YXw98QrpPiW3uZ8GCYGByByueh/MV2mt2q3viHU5Qqh9y7WK9fkHHvya8zW1NvuhJ25G5snHB6Vp6dezF0JkmPAxOjhmA7Ag8H69ap09eYOfTlNDVpo4NWTzMKV44HKnPB+mfX3rt1lNyYLVJd91JImzgbsZDZ+nHWuOurDTprhJW1Z5EuE2s+0KN3pj8K2fCGlNpN7JJDraGbGEIQOMdxg/wBKzqpNXKp7nV+OIJE1m1lxiGSMsSB1ccH9KwNQSSO3kVGnUlQACAEZR1J5/SumudafUoJLLUtNEjKc71bC8fxDHIrl9Rt7SMeR/al1BGuWaOWHftB7A8d6xpXSSZrPXVDHXSZFbZeuZgpABz+WCPyqoJJVlSWyITCn96vBYd8jv+NMNlNHeJ5coeNsFXa2ZPx5P61pLpkbWcX2rUBHkZWNIguM9wSc+9bXS63M7NgiRNIpO7zOGyHO7PXPauq8L6pI2pSRCYvGzBV5yQfT3rk/+EZuLqSOCOSZww3bnwob+tdNpGkpobCZwj7iERixyD6DPrXLiORxtuzoo86d+h6SMtgc4FYur60bWUwWkJuJ1GXA4WPPTce3fip77Vo7PTjL9+YrhIwfmZj2rm5g8EMdpGGkvnJkd85xx8zMPT/CuCMOrOuU+xdS5+03om1OUSzYPlRpHuVBxwq8kn3qhcaa/wBpeVNImWEDKv5YGT15zz+NaHhu52W7XUVmJXUncVb5sevPU+1bDX8Gq3SQQv8AuFQSOT1z2GPaq5nFvQVlJI5W2gvbrUENtaoHIKqMFCg9SxGD61tppGpx7XkEOOrLGTwe5znn8avXxFlEJlyApGF7E5wD+da9zdNCjNgggd/yqJVG+hagkczFIkD7pT5CxtgLM3DD/Oa3Ip7cbAGiyxw21uAKpC/vmX97HBLAxPGzt69a07OO1vrEp5SID1XHA59+1ZSVy07EUFwIlYMxJw25QO/GKPt5SIEGMMx2IQflLHn8qq6rpclkjXdm+ccSLySFz1Xnj3pFS2Gm/wAbM/Iyc7vXb7U+VCuX7JYilvgMZSMk8kgE9Dj3z17Vro0kZ4bfgcsD/P8ASsgeWLeE2zFFIBy27heOBmtGFpSzB9qDnbsGSP6YqbFF1LnzXccIwYZAX5unHNK88kqGe2YlCD8sq5XI9MfSmhhvQ7j8nfs3p16VA37uNvL+UEnaqEYA9aYEJgunAS4B82T5ixX+VaYhkjVl3E+WqkAnrU+lhXiXKgkHJPU5q5PG2xinDYqkr6k3sQiNUAMBUMBgg/p9KaGjuclMo3O9fWhY1AYpkOPvKc1GkomuGQ7hIowckgD6fUVSQiWOT7LtDZwTgEmioZJ3VzmHzMdSpBorRaEny1ezyxaLPNbqn7xOSDyOcZx+NY+k/ZrG9gaIB858zb/Evqfx9a1NMtmgnVdQUvH/AAc9Af8AOKt6zp0P2JzYW8cTk5cqMFh3Ga9NNL3e55jvuS6l4ilj1BbLTVR2AzI79EPPTnrVOW/uZtx1DT7a+RTwQmwgZzx7c1XGk3Eki3lkiyiZF81NwBBHXGasT2epKpd7RliQEAeavH+cmqSgtES3J7nR+Hhpc8LNYQLAzjY3Td7j+dcT9l8hriyZdvlSMF7Hrwc9uMV1HhyE2zebdvEruc7UcMQc1ravoVtq22TLRTABfNThiPQ+1RGoqcmuhTg5K5xej6Vb3erTWoDxnyi6uvVXBwcexzyKj1jSr3S5yLqINA33ZUB2D39VP+c11uhabb6M7yoZJZWGC8hGR+QxWk2pq7AyRoUGcgnn8RV+2fNpsS6atrucLYeJL/S0CW96LlSpIjnUvx14PWsq91y11K8Et7pRindQGe3kCknPBz6Y7HNdNqthp17IZFs4VB53JGQVPrxg1zFxo1qATB5hP3QVkPB645zW8eV62MndaXM7UDE90Eh+3+Sp6PImQffAp8kcF0D5ULRFfm/0mQyNn1AGAO3an3NhLGQ0k8kLAg75o8p045XkflWzpOn6heRobdbKR2bLFZxg/UYzVtpasSTZm6dpyr5kymTefvKmEAHce1V5Q0RkRZU2RjO4YbcT0A9zXW6loN7DYzXN/PBbW0Sl5GiO929AMgDNcXHYxwl53YIhJKkndsOOh9z6/hRGSl8ISTW5nKJ3U/a532E8Z56dvf6dK0NHgt76c75orSNTlppOenQKo6nvVKyA1WfkSH5ucHGFHp7/ANK3EsEhaGGxRppJ2+SEAM2enSgDaCaFYoWsLVtRmyFaa/b5AT3CDk0Ppb6rPDC1rZ280hKxyWiFd3BOGGcFfX0rStfDcUTC58RajFYrjmFZBv8AxboPwqwNf0jSJ4ovDtn58p+Q3M5bH0BPJrC/SCu+5rb+Z2OQ1OC+0m9Tfbm2mOSVYAo46HjvWlp+vW8iLHdeHrKeX+/FmM4+gH48Gs/xNf6hqUvnajOrlHwYo0woIJGPf602xhzbuInBIGSS4zjv+NauHMve3I5rP3TTvdQkRm+w289mxJAjFwX+X0ww9j0p0uqXk0StueRgMtHjHH1FS+FtEfWdReOJpDFGAXctj6c9q6yPw5pzSSRi7EcyHHmRtkrxjGaynUhB2NIwlJXMzStRknCh71fPdMFJlyAPQe1T2V9b2106XsSk5yHQHbn3B6Ul9o8+g3MJlVZ7Fs7ZUAABI/j45x61jahcJYeadzYucxyoVyF/unPqDis+WM9UVzOO519veGRvLjAR4xvYHBDDuB3/AK1d1RttrDOzyO6tjepyI89T7cHr2rE8OPb39hDdw/LNu8uRQOTxyfattLybTlXzEkuLcPwEwWyOo+n+cVyzVpWR0wd1qWJ5rJYB/Z4jadDlFT5i30/x+tWtPgSKwu21Nit1eKwdlHQY4GfbpS6Rq8d2xCWiWzH+EAA59TVi+WKaMpI5aLOQqdd1c7bWjNlZ6pnM6bq1xawm3khGxCEV921SoGB8oB7V0GnXemQWro1xud8O5CtkHA4rMgtrq1kM7QboScKEBLAcn8PSrEt7pb7o5VEcjKDiRCCR6YPermlJ6L7iYtrdm7prQ6nhg++GKQEAr94j0zW9cRCaPnIPHB71xekXiWrhpXEFsRhFIIzz6Vty6/HGwCQTy7hnIUAfrWEoO+hqpaEkekXaOAt4ghY52GPJ/PNWyqWEZhWQNK/QNwPc1FFqwcKSPmPIHUii9lt7hkUOrOw4Ud/xqHfqUMN/Kmj3sjZYQoWB2/rnvWc9ml5Y2jmRXnjUkbx8oJ9ApHPpWjrJRNLFko3z3IwqAdB3P0ApsMCoYYocAxctuAAI9TVLRaC3KzS3ltcL9puMWvChAAxz0PXtjJ46VqQyyW+fsiGcMcNIzHpj8ulVYoILsyJ5KwLE2Ajrhm9fwPtWxp+VjCKqpH0Vgc4+npSeo0G22aLcGklUkBghJKkevp9adC0km4GUEN8sY5D49+nFT28yyebEDiReWQ8YPbJ6UXtxiyMUaoJRh9sYyDzwKVirktjqcFqEiuCwkY4PBPPStRtRRmK26tK4HOAcD8aw98E1nFJtO/A/d7eV9OKvJvkAeNAnG3Gc559PSqV9hPXUW4M06qHg8tyfvK2V+tPaE7jIvDY2fd7ZqG5edduzBIl27Q3Qf1q+jEBgWzzg9BihICCRoUclgVU8bmGBz6/40U65iae2kiDAEjByM/hRVrzIPlu71SBwqoFlYAEv2B9qrwSySRDzCCqtkIh5I9KyNh3qAQypnBBq7ZTS7toOIlILkfw+/rXrqCS0PK5rvU0ZbmbSb2G6hVxby9I/f/8AVU+t+IJpImt7MGMmMM5x8wBxxmpr+4spIY45f9Yx27lGVz7GqF9od0b8SQHc5Azk8gemD2pR5W05bg7pWRnR6faTRErIS3UyZO7Pf8vSpo9evdKd/skqzxp/DIPvdOKsX1lpenBFvDP9rYZ8m35b69cDNZlw+jtHJIum3qHBZpGuAjD8DkGtdJbq5G3Wxdbxdfbty2UQDAEgSEgn6Vej1CO5O8jyp35PzF1PsQBx/wDWrgbtbnzfNsnlihyWXzWXdj6KK0bHxFdWKR24tYnmxjzHYhfxA6803TSXuoFJvdnd2Wh3LySMl2WZzuU7OFz6c9KnHhu/hBaOeOV87tynGePeuTtPHWpJkS21nKoYB8KYyV64znr1rufCnijTtbUQwmS3utuWjcc4z2PcVzzdWGrNYqEtEc3L9uhlYTWU0ltzu8v94COvbvUVs1oYcQyG2uRn5jwQfcV3PiSJ7bRZ306EvKOVCdc561l6ZZwatpBl1O3XC45YYYY7A1Sq3jdkunrZHLpqU0kkem6qp1C2mPykZV1b3Hen+KdH0bTfD9xNbwy+fkIiyuxJJxz1+vFR6/qGlaXdINLtjJfpICGLsQoHvXI+J9Q1DWJUnvroMM8IoIVTn07VsottNaEcy2Zo+C9Ll1rUU05JPLATc8oAyEHoO5zXoPiix/sHSYbbRY5IvMz508S5lPT+Ic15baXU1nJHdWkzwSoNgaE4Yev4Vffxhq/mlW1eYNs3byAOcdF4pThLmTvoOMla1tS9FYy3Epa1s728z6RMwJz3YiujtvBeo3YW4vbm3sQeWVjvYD36AVybHxHdxLLEusMDknPmAEf5IrQ07TdVW63jTb667EyAtz75P+cUpNvaSQRS6q5rXnhNlX/RtasbjZzsHB6g+prGnsb7Srk/aY0VXzhkOUH1q9/ZrwT/AOm2E8C7cEyREgfl0oXypAv+mOCR8ik5A5689B+tVFvvcUku1i74Q8Qf2JcTQy4+zXJBMq/w8YFa1v8AZJ5ZIJCjNGx2sjYypyc+59a4W9imtJB5oDRyHJxkcdjW9pFpAYxI8cwjOcujZI78+o/ConTj8SKjN7HdaJdw3Esui3zF4Z0Pk5yMeq5/lXH+IdLk0uc2cwAIYmNzwJV7cnvjjFdH4etbCa7iaDUQxU/cYYfHoM9/arvxPtZJdNs5IULvFIT74x61zQly1OVdTeSvC5V8F2uma1ohiuYFF1ANhlQ7XwOhyPTpT4bprS4ltZmiM0BIyDy2R1yfXjiuW0uXULCVLjT2UNuw3ICsCBkHOPzrY1m7tCbfWbaONo5sxXUT/wDLMj1/zg0Tp+8+qYRqe76GkzOkkd1tdQrfP5RHJ46jvWlYyLHGzfaCJmfcQ3IA+g6Vl+FbuzvHe0uHK5fcm7hWBGcCuh1RIbWRTGBvPQDksD2965qmj5WjeGq5kSwaxDHJIyyh4lJQhefxqPUtUBw5VlzwCvOff1rFKK1wUt4xGOpVDtyeOv04qU6cZXJeaLYwC8oNx9vp74qeSC3K5pPYsHWLR3CyyhHGDkoVB+vf8TVpdQa5tyLOMFQoG9flGCPc5P4Cqp0a2jKtCGkK55f5uvUe/wBKsx2jSFY5HfauAVO0cfqamXJ0Kip7MbDdyx5H2WaQ+oBVT7Bj7+grQia/k2uGggkBwI0i3FP95iauLKvzeaSVXADZ+UY7+xodlypgf5WGARySfrWbl5FpeZQjguLa6kuby5MolwRI3Jx6AD+QrYtWDyrLNIckHap9vaoLaIi433K5IG1TkDb659zUdrPCbqWJWdIsjy2U5ByeSB9TUvUa0L010bS+QyQl4wpZpNuQv5A89atRTxbhEjJGgHf5cjjFUrOdr6eS3tpHmKHy5JAdsY9QD69PyretNJgjg2yxjJPzZyfwpNDRlXLoMmyLF3Uncm3HHB3E459xXQRzWi2YcFMBc59KyRYxaK7TFHksyQN7HcYfbHpz26ZqG8ll+2RSW8KfZuORj5jnPXoB0p2Hc0bJJOVmwyHk/KAV96so5jJjKkJ1Ds3A+lVUkmeRoLceUQu6Ru+evfjPPeoJ7pxDvQR/uwFycsx7bgtCQ7mhJCJh5Ts+Qu9Qh25/EGmwTSR7Fu4vJkKckMCv/wBcjFQ2VwIiDMVEp7LwAM579KjmaT7bKPM+UxrwDu2nP3s+lOwrmrJNCUZS4f5Pujn8frRVeRLM2axnb52z5DnnPY5HvRTaJbPnSy0dFtkN4ytJ1YYznjFZWrWYRwtiHXYvzY4P/wBeu0+UKCwyO9Urq+s7dVEgT+lehTqyvc8+UFY4NDcZCySsGU5XkY/D/Ck/tS5MwZbqSOVO7McD6g1tanqsEc5MEQDkjcoGVOPUVTtoEnug01uhzuKep/CuxS0u0c7jrozC1e41PUrmGZpA7xjCumEJHoex5qgllfMzi6L4YZbynA/PNd5ceG7ZVTJljVsndGMgfUYp9voOkfu1n1KeTPyLiVR+FHto20BU2cJHZO5WTdPEACgfasnb0BBqBY5E6N9pjZsBkByPTK9RXo114T0tmRLLU5I5AThZSGB68Z4wfxrFv9Dl0yVGvCrKX4miBUr9acasZbCcGtzk3VC6BxvO0lo8YOB6/lVnS7iXT763vYRiKLllBBytd/YC38Qxvp2rxiSfaXhuEGDgd/Y/oa5jWPD91od00F2S0Un+pmRflb2Po1CmpNxe4OLXvI9n0u6W8soZ0J2SKGHuKi1Kwa4geO3cRFgcZHf1riPAPiKKzii0i/kijUZ8iTdwwz0z7V6LvUsrZXB6HNefKLpSOuLU0eE6vY3lpfzK8DEfcyBgg/X0rAuY7h5mCRsckkKvzDNfQmsaXaTq003yuFOCOMnNeM6xDc2d9Myzb40b5VXPTtXoUqvtEclSHIzEuIbo6VI8ULmPIzKxwFY9vf6VX07TriGVHvHeF8gBh1/z9K7K91S01Q2KJCILOMsxRRlQ3HUcZPXmjS5tOgvIrm+WaWNifl8onCjoRnr1q3fdoE+iKn+qiQfarmZiBj96xA46EHuK1Iols7dHkuJwxOQRIR6HjB/zmtO917Q3Vls/DMUq55knYJ/LJrGkvYW3hNO0xcZ+/G7bR6ZLc1KvLdA0l1NfS/FGs2kDRb0u4ScbbgksAfQ9f51Lca9pt3aBrnQlE5BAkilAJI6k8fjyKwItSsItqz6VFKWXaGhmeMA+y8iom1GziIKaZNzwS18+R6jpUunG9+UpTdrXLo1YRyxSwxo+AB5V1KGX6cLx+dWtEkW+1aKwtmjtTcE7IiS6Fh15HI/HNc8lr5s0ggihWJBuxIzyjn6ntn0p9osVtLFc287Qzn5RsbbtPTAx2qnG60JUu53F5oN9p0R822dm/vwsNu7OFOeox1967C8vrC+0dYLrULX7UVAP7wD5u/evKx9smmjMsdxNkBx9odgpI6/eIFbEdnPeFEtUsBlsiGS5Qde2AfyrmnTvZyexvGdtkI0kVheXMd6Q0KH93Oh3JzzwRxnnvjpUWlyxfbXkgYtG2FdGTcGGOhBq1qHh69XzHu9NmEz9ZFTcAfX5T0x7VnR6ZKd0ayGN8HcshKc/XqOuO9XeLW5NpJ7G4mlSWaNK6SzWGQQzElocckcdR6Gtu2CS28U8KyzOvTe5zjtj2q34W1WztbH7HNDJG23B3tvD5GDz0P0qhBbpp2pG0t5d9syeZbn0UnlT9On5Vxyk3ozpSS1Rt2UYMYcp8u45CAE88jNX5BHIFMKbZCPuq3Bz64/nWYzyRCNc4QrnfnnGOSf8moo4Lm8YvBN5E6sMktkFM88DgnGOtc/LfVs3v0RsK7xPBuYBlB6+wxz7g0faIri4iAZ8yJvG3pj1J6VSaA3VtIlzH5KKoQu2G3g+hz147etOjRLCyt4ljieLZghz2xz19sdOlRZFJs0lhhEJVMRjJ3YHy9PX+tMTylhSBZII2IwQpwffbzwaggjkb5oproQsvAQj5fx/DvxVfVNMiudSjkmuWh8tMlH4L/5/nUpK+rKu90jfjuoJraOWEyYdfl3qVLEeufpUCWy6nPcS2yrDaqdkr45duMle/TjNIkEa2kLW7KqIc7CgO8nsR2PP+cVseG4VisTEzb2R2BYfxZ5P+fap9B9NS/YR28Voi2iRpGq/IE6Yq5bMQQS2ST0HT/61QCEwoPs6Ko6FT0p9osoJ3xhSPQ/rRqBoFFkQxsMqQQRXJ2r/AGG7n07/AJZRkSQknOVPVfwyR9CK65flG3GFwe9coPJutcu7gksIgIRt6YHX9f5VQF1tPS8kMjFljU4UIxUEe4B5FZl/pAm1Hdp8cInyonlZScY4GM8Z5/lU+py+XFO/lMoAA27iG3HgcDvntWjolrJZWDLDOJ5Sd7o5Gc98U1dag9dAi0OwhU78lwMu0hzv/Pj2qlb6FG1/JLbSSx4b5WDnaf8AJNaSlnuXSWMb+CwVgSpxnrWnBGzEMdwPcH8eaE2wsjMaOS1DLdCMMDlXA4c+nPSiovFErxpGAzbWkVdmfvc9vTofyoq1G5DklufJUmo6rsVftZnBGAJBjHr07+9Zkl5dTSsssqHJwAPSlknMs223RvOPBVuM1Ut0lmuFklXbJn5No5/KvcjFI8dtvc1rXUI7bexYnHKllGfxq1PrhmgV2kLOSeF4A96yZ7UbWBccDc2O/fgVmmVbWBirrukbbt5JA+v0quVbiu9j1jwxqS3lri6lUOuF+XtkY6981euLDTEzNIuXTOQFxyO/864DwjP5sgg8wMS4GejY4ruvEGj3DSkxAzQ4ywLfdb1ArknFRna9jeLbjexHfXXh2zdZ1WVZSMqqITuP0qjp2q2l48lupaBpDxDIxdGP07fWq13pcwmMiRl1K/MD1yfQdM1QedJGjWGGRbpm+RNuCrdsY6/yq1BW0ZLk7nc+HktNMQq1s1vODs5Gd30PvW3qVhb6raPFdIkkUgHy5wV9wex96imlsZoIEu5I/NOMKW53dM4NT2sUbQhGLAMNyg8fTFcTm782zOhRVrHmms+FZNInkYq8tjjKzYGV9vrVnTtVv7WKGOKXzbTaD5UrHI/3T6e1eg317bwWzxXDjB+TDd+O9cqdHsb2aY6bcm2l6PHw0Z/PlfwrrjV54/vEYunyv3WZ+o+LbiS1ZWgbd93LEFR75rnGup7yGVPm3S+g6jOcjPWt/V9GtLEhdSvog4P3ACxcdeFGe3euksLLRW0k3cHlXWFGBnGOOBjtWiqRgvdRDg5bs8s8Pv5T3BdU8s5BJPt1AroPGV4pj025tpEVTGuFHQ/Lj/P1qteWUTXTGCBo4AxB9zjkVzVw7RYzzHE7EgnIA44/WtrXaZn5Fi9vFYxCORRIy7mKg5z/AHT+lW49JF9EgQlzkZLl9v4Yxmuc05hdXJjZQXJAVSOO5ro4rh2lEUEmF3AkBjhefzovdDtZlzS9I8hyZra2lQjH7wuFQ+o55PtUN5pSO4gDW0JdsBiW55553V3Hh6ewi1BNO1LS7I7yQkygtjHTO7Nd8um6ZboGjsbVf7u2Jcn6Vx1MTyOzidEKPMrpngkOj722rKFReMxozMfbqc1r22iyxyAwxXpLjHyREHd9cCvclkg2jy2UcZ2j/CuX1zV7z7W1vYOkbgjDE8D3IxzURxMpvRFSoxjuzh10S9toJZ7zSrkqmCXkXPHckk/5zWj4bmGpTJC9sbeJCD5qoSQP9nA6+5Naeq6vqIsprK9K3UcgG10G3gHPOPpWjp8oksRJPiK4VT5Z6ZAHHPYe1E6kuXX8AjGN9Dpb/UYrO2VoxuHQc+1Ykuq2OosItWs2tyWGyc4ZQfcjlahMTaxZJ5R8u4QhsEYz+dV7Ubp/s19D5N0mW25yWH97PGfrXNGKS8zdtt+RYurX7DCqz8xsciXqpH1rm7xo7u7igtY5HkjfEchbcoXq2fUdBXa+HZ0jvLi2BH2cAHyy25UOOcE1XlaG+1ye5tmwkCCCMquFbnL/ANPxqozcb3QpRUhiRiEh9qkqo3LuzuX2z1Pt61eX98FkjP8ACOCuGORjBHqPfNZ2ryQh4i+57qN2KW4JyR/e9D65NadqZjJHLbKqR7cbcj5iM56dazktLlp62Kcdo8ZzYX8skZO1llbf5Rzndx1HTvWraWrTsxkk3qhComMAN1JOc/SoIyjQvDawvcXDEs6q3IPXBPQfSrmhXMdwC1wjRkZADtk56dc81lLmZpGyLRypXymRZc/MGHUVBO7SzxuiBZCOGPHf/HFPuruKIFIfKJQnBZxuA5zVW0nivtpQGMxHJZgQWPtWai9y3JbEEzXFvf2/np5bR8gsxZAf4iCDz1GAa6vwkrLo8W/JLszjPUgtnJrB1P7VLH9njykcw2l5CNoP+e3v1ra0jVEjsxFcqkTQIDhXBVlx1X2q2ronZnRpjn0Pv/n0p2MMWzz1IwfesS58SaVZQ+Zc3ixhgDt6tg+39KzrnxjEqhrSNSrZIaZxGp9SOcnHoKapyfQOdLqbmu6xBpMO+4R/KZWw69CecL+fFYWl/a7exWSZGeS43NJzwCeR+Vc3c+KLaS9+3ahqEV80a5jtIoiQD/DtHQn3NamneIbu72qNP278tiN92F5wWGMZPTg1cqUktiVUTe5c1Rp7izKLGvnyceYx44bggfnmrehXhaMC2SYyBR5rSnoQfu/nmrMcwu5E82N/JcHA2/dxjhvqcYFQ3MUcbGO0EsQfOCVG2Q4yTjr61HSxfW5t2s4AICDcR8oz97PU+9WSQIVaSbZtGcd/Tt/jXNppckFpLJcXLbNuESI4wPYHpx1os7a9u9rNdb7cBSoUhD3zlhz0/OhILlXXtWjm1NIJ9wsnYLLJtJVG9c+1FayaPbyxqyK8M0WQX8zIIPBU59c9aKvmSWhPLd6nxo0+ZPLw8kRwPMztb2qGaKS0xMjDPUq5/THrWxOyQW00c+0vjaB/X0zWcsRuJfKwI2UEMAM5+rfSvcR47C1uRfsXMZznqnP+cUmoaaVu1mU7ucBQOfx7fhTSq28YaB2APBZeg9j/APXqOSW4iDlWJAI+YryPyqrdxX7Elow0q8huomAlhcPnswznBFegr43N5cLENg3jAI9PpmvNkmmadmK5j481fvD6/WpY/Ihk81Uwy/LtPHJ/WolTjLVopTaPcdNSSMPuYXBl4UcYHviq+to1hpl21vGv2nbhSqjI+hHPqa4DRPEQaZ4nllt5sYUM+QSfX2rsNMt9Wv5XaSaKSHGSBkk/Qiub2fK7tm3PzKyOWjhkS2EjyyMzYYHrk+v611XhTXZLi4FrdNIssSZKj5sY4Of0rA1HTL37TM0MRAj5eNWPvyD2+lY9q9zp19HdWyMJkyxEgOGHcH2racFOJlGTizvPGlzLLaGWDPm2487Kr95RwR+RzXGpNdWbw3cErxrLIACB/T611Wl69a6tZFbpPKG0rIhGSM9cH+lc/doloXhgBkhyOAv3f8OO1KkrLlaHPV3RFa3S32sXdzPcBJ8hT8oIbv6/SoL57gXkL2TlvOfa0YPAJ6girel6QLiaRvOCJJhg2Rkc4yT61Uu7W50+8mhlbfLbSgh1wAwHQj8P1rS6vZEW0uassSzWosGtXhnGQQUwfbPt781ypsUtWIuFLQSM2GxnoOf6V9AWxs7vT4ppBFIViDZJ+YDH5ivHdeeOa6up4EZLSJysYC5BPfmsqNVz6GlSCj1OLtE+z62Nrny2z1PXPFdd4W0eW+vXWwaOWSPDGNzt3DPQH1rKgZb3SJo0szJcjn7WwJxjsB9cZP0q94dvJLaaO4gkYTpnKE4Jx15NXJOz5SU1dXPQINB1l5Imkt4oo4m3IZnBPf0+taYt7qMI1xLPO4AAYEALjPQdqdpXj7SpbRBfNNBc9GXyy24+xFLL440dmKpbXUrLxt8oKR+ZFefL20nrE7F7NbMRVMplZr5BJggA8FTVWy0261K0kubWWOWcgxSqx25I6Mreh9DUF94mguY5Ta6aEbsXmVefyNM03xNf20EcUVva2/mYbc5Lk+/YVShUS0RPPC+ppaV4Wv5J0m1N02LnbCv8OffvXRDQYTaNDj5WGAo428djXGXHjPVVdyk1rsQAZEf3ifXJ6VO3jPVY7eRwLGQpgfdIyfz6VMqVaTuyo1KS0RLHBPp96YTI0LnJQsMiT8D3/Gr2sreyxqk39n3SKmd8sDK6Z7Ag9fyrl9S8WX2p2Xl3LWCqx4RY9xHTuTVK4gnntVD3cUMbNnERYA/UEmtFRk2nIn2iWiNyz8qz80loI4jjzNhOQD0UE+uPwrorBIbizQW7eYCQQoIwRnkcen61z2gQjT3cyRW90BjdFIp6/XOM+nH5VPPqMNrr0Euk2jm3vOJYVG1oZF4PHQcYqKkXJuxUHZanSahbRnbM0G6VRsTnOAcDkDqByetMtIpEszDHKpcN8sgyF9fT1q+sgmVGDNjIBOfu/h+NSPDDNAUE205KuIztyM8gkfzrl5nszflW5l6dNPFp72QRkv1Y8SDPXnfnv1J9anQyWCQR3k9sU+8xJ++TkscHp61VudTe21UosOUWJiylto2jHOTj2NWNBgi1ErdzyNI27gkfTpTkrLmYo72RBEsl4CbLT5TE53xzSAKR9PQVFcLcRXttDfu7RyD7qkAA8kEf/WNdbdMY4fMWI+XECQwPX1Fc3pU4W0F1qTxSTFydrlWMak8GlGV1ew5RsWdPubZLTzJJkhUv+75PzfVieT1xio7i6mjczXDyKVJWJIUBJXrzwT/LirlzbW+rRwKISqx/vIyqgDeOh9BxUlvpn2CNJ2hhnvgGV5ypJfJ74/pTTW4WZh6x4NvtRuYzFMEiKlyQx3jI65P8sfnW7D4d0/yI7S6WWQNGFZjI3+s9eMYPSnap4nstAtxFqkwBCZCKhLKOwyK4fUPigupXcdpp8NxEzPiJggLsCMD6f/XraMatRLsZuVOD8ztNO0S005TNqiW6zxf8tZH35xwDyemDRJ4p0e3y9xfxKFA8uFOQwxxyB1JzXJ22k+JNTdZ3gjghkz80xyWOOmT6ccis+5+HN68k0t1qcRAJYgqVX6YOMk/pV+ypt/vJk+0mvgidY3j3Sor0Ri5hSFz94sdyjHoBgfXNaEXiKEee9lFHc/KSZI2wBxnGD1PJOazvD/w90uO4aXULOa8V4T5ZYrjHboevbNauu+A7G4tAtkJrNmUspZjuVvrj2xiplGheyuWnVtdmsNZ03UNNimknAUrtbY2CM9h7n+lOs7VHlae3crASH+bLYYHA4B9P8a8Z1C313w7I0cDWt4LhWVtx3kAf3lPIPuDTNB+J2r6faPBcpJKsgVhNI2SoGAFAIxjpVPCN603clYhLSaPoLUCGi/cttJPLdtvpj/8AVRXnml/EK2ksjLq8DraysQsioV2Y6cnrjpmisXh6i0sae3g+p8yzBp7ZckvF/CSvzAg4zSKGVXjWVldlBYDDHP17VT/tH7JekwSbUdMyOHyGPfitOAwahdwhWijIQMRIR85A5r2E0eY0yvO9xEwmmfKMfmXBwTjqc1nneziO5ukBJ3ktkHpXR3tmNhckuJAD8rcBfYHmo59OtngKSR5IQYLEt+IptCTsYmnIfLnMILpuADdCavG1eYLJ1XuR0XjkfUVuWunFtMj+ziJ1i5k+UZH4981mql1aKkcSsYwTlWj2sSTjbTW1hN9SNMtAkSqDubCEjbvGPet3w34svtAlc8y2mQPKfg/QGsnVpY5bYAAiVTnJBDK2MED+VSrarImDJv43M23AB7GlKKkrMFJrVHrGm+L9BulHn3YtJXxuSQbC1X5bPQtegkiheKRiOcHr7g/1rxzSNKu70mW2hkkjJwGB+8fz6Vp3VtqOlNGTBe27MMhyCAD9RXN7CKfuyszb2ja1QzxHpNz4f1SQIWVGO6Nix5HpW0upJqelBR/rUj/fDIBA6BgOv1rH1/W9RutKEd8UvIwR5UuAHUjpyOo61naSks0SXEBDy5G7tx/nNbpPTm3Mr9jbSXybbEaOXi5UoeGX3+ma6/xLoj3N7aXIC5mhj3t0O4D9ayPBoNzduJfKOVC7S3J9wPUV6TFeKumySTRSKkCk/OOcAf8A1q5q1VxmkjenBSjqed6sP7HZNOs7iVpnQCQqceWCf1NYeo6fdS6e0lrJLJZQttc57ZwRRIz3ZeaRysszF5ZHGVQE8AH6V0z32mR+HbjTrNbpYlgO6UwEhnyOTnkLmtW3CyRFubVlPS9MWPR0KojfKf3Y7ZHP449K5/7NBFestqPmSTa+/pnnofTGOtdZp0zRWsKpYXLTSD5Sqk4Pb04+tZOrWJtbi3tJzE11uaacqAV3tzj8MiiE9WmEo6EUFp/aGpolmyJKPvsxAWMdzWzqXhzRbWKRp9RkvLlFJ+RggHfoOT+JqDwxpLTvNFqMjtah8BFO3e2Pbk9a6mXwvbzwlQdjuAQJR0PfnrWNSqlKzZpCm3G6RxmiaM8KtMvlXAbGIpy3yE/Qjj8637i3OCsNlpGQvJNqTj6ZY+9WLjQpIEDJEZZUOAY2weOnv6etEGjGfHmeVlvvSPJI5U+m3IH41MqkXq2NRa0M2HzHMlrCunbghDFrJAQB1qxpt5NA4WO105yvLGSzCAdMEkVrxaQqoFa20tZGzuDWzEkdzvJzSwaTbb3Emly7xyJLe6YK3/AXz/Woc4NFqMkTW+vS/Mt/pFlJHnAMAHTHXBHT8qmj1HwzOu640rymOMn7L0/FarXOnTxgBnvIoc5BZUmAz2OMH9PpWXLZ3EbP9luDcK3ysZrZoRj6/wD1qhQg9nYtymvM6aCDwrdAyW94In6lhcspGPZj/SqtrpmkvcyR2l5HJCW3BWc7jJ0zuP8ASsHTYLmMK81va3KAY2xygvu9CODWte37i2aE20vltk7ZFGMY6bh680ODTtFsFNNXaK0FzqNhrFzY6hmSNHAT5fmZW6YI5PSug0q1iEu+0klYEsBEMAIT16/19a5Hwxcz6xePJM+ye3jEWxyeik/dz7YH4V19jGIocSQSiRQXXaOV56En2qay5dOo6bvqUvEUB+ys9yqESOsQcnqCeR9Peuv0xo4LRMwhY1XGxuwHA5riPFLbLNW+cyOA6p8xU4YEg9hnA9q1U8WWe5IrgS27sQPLljI2r646k/mKynTlKCsaxnFSdzW8Taq9laPFBbl5pcBEXjOfb+tY1jpz22nQmREubtQN4PJIJ9T1GP5VAbm51S/juolddOiLtCSv3nxyMdQOOtakJdZradibURxgeUGBRmOMgknp064qbci5VuO/M7mvZQLbLGYpDNC6KGVs5HArjfHXjOPTnksLSN5JnXeWRsN9Af69a6q/uUs0DebFHbsGWV3f7hA5OPT2Hevm3U9Sa710PbyyJdBgFdWOFP8AfBz96t8LSU3zMyxFTlXKjqLfRdTvIRqmrXNwltG/mTREMSoyOTzkZzgHnvXeaFpsN1cFtLtZNPlTJ3tFgFcYODgeoIrlfDWtXmmxPFMI9Qtn4nkYb5Np6c5z+J6dK7vw9rNtDPbQxedDFBG0bpIGWIdz8p5JxkZB5roruok0Y0eS9z0PR0ZtPgWTIZFA4I5NX47QrI5cp5bAHBUEhh354rjNP8WWSXktsZUWCAAJIBgbjnj6+x611Wl6tHqZkayy4GMsykAD8e/WvMlGUdWjvjJPYs6bax6eBbxtI0QG87jkKTnpV2RkRRISox/F0AHvVdrQNM0uWPYoGwB6n/61VktC0O1Lx2Un7noKXMVYjv7Sx1CcW0lvB/ekDICSDkY+teW+JPCcOn+JXuECT6fsMawsu5hkEkjb2H869PeK6ivRcRXMkyIuzyAo2njqT149KS9slvtswmCKhw4boR0/UfjW1Os4PQznSU0eb2fhxP7Mit9YWMW8RBhsnjC5wM4yc4z19+elFek3un2OopFG2A0Jx8jYdcDsfWitvrDetzL2KWx8OPpFrdxO8c0IAOAoH9RUsOgBEYRsgl3fIAu4HHUZ7Vlxi6hcyJKpyPuAcfjW7p93K0cq3QfLAOpQYX6nPvXppXex57bXUZd6TdWs26C6ZpQAVVG/IHntVee6vjvZ/PkBUbhsBx/nmp5JUclJ7kxvwcZAGc9M/SmuTHcP5F0ojJVmDLubjoTjtnjNVbsT6jbWeRZIyElUshZcrkv2yRnsa2pdsztJIpwVIz5mdx65Oe/86qR3traXLvIpUs2AY/wJI/CmDUmfMy27tZIMMmzknsTnj+tVsTuTXp85Y95eSVAR5RBAwe455HSqs87JF5cSurcqy5wPUN+FbkNvJcqssckLQFdyxHCkAcnknnmqt6g+3FlHkjJLQn5uMcYPejcRu/DLWjp10LC7dBFISySN6/SvaJoINQtGjk2yRsMcAH8a+bLiCNpI3tGYJ94lR8/5DtXZ+E/G91paiC7jeeL+FwfmGOBkVyV6Db5obnTSqpK0hnjXRW0a9EQVzayHIY8qp9cCuf8AB9o51CSJH2sy7lLHHQc12Pi/xTZ65p9vBHC8UxcHcxycdx/+uuZFm0NzbXMUcp2N867vvc84Pat48zh725i7KWmx3Og6ZONTNyscY2xtjavLcgZ+vXml1XxdPLcNa2loS0f7uVc5DnOOP5V1fhuSznsxcWce3eArEcke3H9K4e6g/sa5ubW5hlDtIzrLtysoOTke9ckGpyfMtUdEk4RVmWI4X1HTorywtsw2koeSzK/OpA79N3rWbf6xaOkkcJy8iEiNAGy3HXPQfU12fgmLyYbi5vComuWVhAMllC9D9TWRfW1tqHiC8mvbcrLFJ8kTgBVTsQO5PXOKIzXM12CUfdTOl0K/tZ/D1pbi4S5ZIVUv0yw//V1riIoVutRuLWKGSW+kbJZlJ285z6D6mrJlP9txjTIypjygZRnDY5O3vtHP1IFa9xpR3STNe3Uzuu4sZdm9V6ZAxj8aiP7u9upT9+3kdS2nWn2GOC4ZYJgn+sQ7SfUiolsL2UR+XqUciq33mi5wPoa5m0v9PyIVnaaQKVY8cke/tVy3uWthm2kbagJ2ryx9/rWHs5r/AIY254s29X0y5awlkkv8IgLERx7cjHTOelcPcWE0QSWzupBwMEknnr0/xr0Cx1eKaAi72mOQcFuNwNZt9oM8aD+z5YpbMZ8sH7yZ9+45+tVSqOOjFUgpaog0OazvQiaurpdnGZGbhzz3GMZx0NVTb6hcyJNojSWtm3KtNJu3A9CAc4/PvVi4SCyjh/tSUmPeH8pMAsw6cdT+NT2Fwi2zRWUMtxZ5+XYMTQ85xj+ID2oba1j/AMAEk9GT6XFqk7TW801u8yAFlkQgkE8MMcY+lW/7E1SdSsk9tEpzuABkz/KpUaO7khuoJpDJGMAop/FW9Oe1acGrCID7UpVCQN4GMe5rBzlfRGqiupymoeGrpbdvtVrBeoFxvh+V9vX7vc1TWwtru12Qy7ctmMeYQdo6d+PpXR63fz3N/PALmS1tYsIXhPzM2M5Legrn4riCwkuo7iVZrhCGhl4JcnHXHXrXRGU2vMykophBo9xHepJHIlvGrYBjHzAj37g8flW7dajAjT2ixq0kS/vCMgLnrjPr7UsyypADGGQbSQ20ZDHOMD8AP61m2n2pkMEibp7tgZptvEYxzkHjPH61DbnrIpLl0QzyLi5ntFb7iqMW7nMYbBww6ZI9Pem3OnyzIJLxfIvU+Y+U4AkGcY6gdAOK0b+0S5SNo2dHRR5TRj7rDu3tx+tVtV1RLHTTfXtxutlkCAEkNx79zx1460JyduUTSW5stPHFYOzsfIIzlR/q1A6/h3rJ1bV7G0gaSW7BIHlbBlssTuBKj+LjgVw/iD4hW0UYj0psPuLlW+cOOwAHfuc46d64y78U6rfa8uqCGJblipjaWMKCoyM7e4HP6c8VrSwr3kTOuuh6P8TfFEK2DaczFvtHDqcMVTHX2OR04rxezkLx/uGdpY/mGFwT9fStq8imvnikvHMsj7y2AdmcZHPGOh61NbWot72IkuYZ1zGZkAyvYkDIOR07c1206apqyOWc3N3ZS2vDEsyTMQyhZH8sqFbPIOOuRzmu88Mf2rdS2wiiS5L8Kt4jYO0c7W7gDt71m39pqUmjafO1vbw6fHl+CpaVgRksOhbHT8a9j8KXdlZ6LFBaFBdOPPtkXOFOMEAYwM8ms8RV5I3SuXRp80tWcxbGXUpbae4to1dwd5XA2lTgAjv9MZr03RJTZoiQM1zI33ULs2OcnJ+h/Sse90qa5ntZJIYbeOZllaWIdHHfGPmPfnNa6jUo9OVbCNPORseaIthePPPTgMfyry6tTntY9CnDlual409rHIRcBN0ilWZflUHr+P1q2s5iYRoRJI/IIx07k47VQg1RJhNbXQiklgw0sUjAN1ypx7mqcOoC9uJLWBBE8bNGDGCxTIGTn2rA2NW7lk8qVQGjULxJGfmLf3RRYealnb7i2SgyTz/k+tW7aIRRhHm83yxknpk+v6VSghvZb9muiogUHyggwQexJ+nbtQrgJqGkRXFylzlo5AMMVPykd+KKvPhiU2qpKEgH/PSiquKyPgJllELSJuQRoOWbJAHRsjrUlpJdX1lJGZJC6kLGC3GfQ/0pmSJmgiYGM4BI64Pf3rXhsD/Y625JkuBMGKgjp65+nbNfQniMxIbVpLkQsskqA5w4AwavA2EUZLpPbqpIbjOAeCOKt22zzAtwiwznPbGT04xxmpJrEzMmSCWyeCowBjqO/wBaqxNzPFzbGMxWQIABOTxyPc0sc8xiG+USI2A8aPgH/E1rpaPHagSW6r82Q3l7VHt6GoJbD7NEy3EXmxsSRICCAR29RTEVXInjhEIaGRDna2cuM/KAO9dZpuhX2pKskjiyXjHmKN4PqAOlT+BdOW4Z754y0iKVtg/zAHoSD/Q+ldppCvDbstx5ZlK4BGPlUHpWFSq43SNY077nC6r4PvLAHyZi8g6nhV2noAc965m7W4a4bzSwnXAYMTzjsfSvZZ78q6LKsJiBCymXBxnpge2a4L4k2nl6hHJbhS7fuwykYY4zz706VRy0kKcEtUWPBFvBqF8wuDG0wXeGIG38qj1NC95drEZfI3lN0QyMdD+XJrmdPF7aj7VE8iMRhtnG3PXHqK2tD8VpZK9pNhAzFuo+Zj6k8iraadyU01Y7T4baxZ22kXFq10v2iKUkbsLlT0IFX9b1WW6D20bs8pOAmRtX8f8APWvKL6aG6jEkUZhIfdujb5cd8d8f4102hXV3FbhoWa5jUZClv3iZ6k45YcfhWDoJScjVVW1yncaJqk9pNLbX/wDpMQUASqm1lJ7EDg/h2rornTtO1gq04ErJjgHBxx6c15vdm5MEl75ZRP8AlqOhC9fx7c1r6Lql5HaRTbQ8fBwDyw9xXPUov4oM2hUW0kdhe+Ho8wyaWkMTxIUVSMqQTnn8a57xFouoTmC3nukUO3IhQquO5Pcn9K7LTr4XAVxtMTqrIy98imauq3MDBGIwM7x0GDXPCrKL1NpQi0cPcadFbIqwhGTB5IwwOOaiF61lJbx3VsFVfuyqcORj8qZqM1xfXLw2nzW8JOZSMZ9QD7VWeT7Xc28Nx50c54jjkPyt6YIrtSuveOZuz9027ee2u1R0udq7s7jjIPGMjuK17NZrCWPzJ9iSnKLyVOeuB2rnbeE2U5mtFwduDEyZUHPOP6frXSq8V1Y+VhoZAARvOQT7GsKit6G0Hf1LOpww33KkJMASq/3iB1/+tXNW2ozW0nn21uwKMEkG/uD9PrWzb29zKrKPJWZGLEJngeoPvWMcx30rOqrDICxYggg45z6expU0rOL1Cd7po3LbUYZdSivII9v2lcToOAGH8Z/PHvW5fvDPZzCVMqyMvTDHjtXDLHGZGjiIiDHeJQDgtzyfbHUe9dUlhqd5ppQSQOQuNyPg5GMAgj5azqRUWncuEnJWscfpE7Tz3cl2HaPzFUOpyAFGBuB9R3qbTNIuNR8QSXsKtboseyMMM7FPTI7Hv9CK6Wz0kaFpN3dX4EkxyWXcAD6DOOc5FP0kS21rJK6PJNIC0jBMbifT19PpVyrLXlJjS25hbA3VuZWuohHF5W0PkHJwc4Uc5NRWupwPBarZrJIHJ2pIOXGeoHXGc88fjTtk0qT3UluBGpOxyGJZSAcBDyOeKyvC0s9rqd8DarNGWwMEAIPQBuPy71CjdNlN2aRpajBOlx5UR+zXPlhREZcLtzyQwIGMZ4PNeQeOfEt5e6kLK1k82GCQhXKD72SP85r0bxzq40i2udTQMLhlMcaSMSeR37flXkeipbaloOoTSXax6gfnEQ5D+gx1LHPtiuvDpW5mc9Z3dkMe0MLQR+Wv26AkPIZAeWOVxxgdSCTW1DMq3drNeSTKlo+HTdu8kKfuBjxnksMce1V2s4r/AEu1t4oZotRUFnkKlV2r1LdSe2T0rY0zTr2wtJWLx3IhYslwsZfcBnoWwMd810tnOl1Ksl1PNPe3q/a2geYsryZAUA4VmVRzwf8AGtu00lFs1WQWV85YyI00Zh8xSvDbvYjgY+tQCa8u9Iks4me2fyzKWEZRZlJ7jOCAScEVHPZWc9pYzyXbzCOIxx2zv+8VsE43AcAkHIOMetQ+xaXUu+F9csLS0msDpcLRxN5bAR+YX3HAwT6A5/DiupW8YXtt/ZyiOOCZoFgVmYluQCWPTqSR29q4pdStb29Pl6VJDHZRExrbKcJJjgjGMc/3utd/8P4Z7k2t/cXlq8aP5jIsgUSGThw4IHzDNc1e0VzM3o3k+VHd+GYb0bMy7ISvyxNKGUHvgDP5ZroSZGiYQqqTOSrbwQOOuOP1p9qYpowBEElAPycHpwKmtd0sm1iQ6DJXGFP+NeQ5XZ6aVkcoLHVbjUnnia0WBQsO3Zh3HXl+4Hb6VsW1nm5kYxxRpHGqLIPvnHr7c8VpiOIDc0auWYD92uCMcc/TmnZdJ8OB5Z5ySMfhQ5XBKxQYNbwySRQyTno6EAYI7gVMZ7hUjaXALBeCMEE9c1PdzxAhZG2u3yqofDE+3rWfbTyyqxhAMqv80gUcgevT9KVxmlODLbEw7XYAEYPfg9e1FV7eWYSJ+4kRJFBGcEqe+4du1FXd9CbH58zYntR9jjfzFXDBc8+9TLPcLZlxkCMgBd5DKPVR71Jo0pebMihUQcAcZHPek1BkeVRcMsyKcKV4bjjGa+hW10eL1sMgmeC6iaWRxITl9xzkHsa255p3uI70yoYnBZFB3Hg4xx7ViXUUV1FEynEh4znPHv71UsoZBJcOHjEsYGFPGf8AGnezsFrq56pY6hp4FuqxyG2Zcy5GSGz6/wBRWFrE4lMxtHGyVywXPKj29jXMfbr3ZJI1xmNkCkoemPT04ohuGEBfy1kdDhl6du5+lNWRLTPX/C3lxeELCdbjY+8iT5sEMCeKvBpHRJoo2aZpAHRHxx2H0NeR6Tqmo2s1ylnOWt8ZY7Rtbjj5T069RW9beO5LPTvIjssSbshy+7n8RWDpvdGvMtj0TVfs1pF9quCxkcgGMqCCO+T+Fee+Lbx9S1QTx7DCgBIAwrH0/KsHU/FF5qtzE9237kckRP8AdH0qYLHeWcz21w0mR8oLbgSP4cEcd61pRSXmZzbfoXbExrG0CDac57jPcjjqPeqd/aNNey3ERjVG/er5jBCQOw4wSPUVRsJgMxRQyh4wVKBsEH1B7VpW8kV5p4g6FG+ZWfcc9Mg9hggHnmtNyNi3CEe2ikdX3k8rgMh5AOR7fWtnRZfsN7Hd2qsEbCyIwIzn+lc0zx2uoGxErojqSue3vx1FbGhnbq9ik7M1oJFDlTn8R+J/KpnqmOOjR73FbR3NsUmWKRSu3aE7Yx+HB6VwtrYyaJPdadcMwUktGf4WQ9wfbjI7V3F/dwaTpLMm0AfdU+vX8a8/8Rajql1aRT3kcYEJ3p5OFkQn07H6H0rzKCk/Q7qrS9ToPDUjJa6hpbESfI0kOCc4x09e1M07WdTi06Fp4Laa3IGEGY3HHuSD/wDWqLwXazMI9TkZ5twwsq4xyeRt7e/vWtLpctmS1lGkkEhZmRjgrnrj2ok48zTCPNypmLYXdpcXkokZowQzRvjaG9j7gdvxp9zp0VzbuJk8oqCEcPzuGOP51k6taCUNLbPLFck7tpAHC9OOMEVpaVLeX9nFLGWldVMcgwOv+e9ayXL7yZEXf3WjoNOs4tc0Yxyo0d5bExuBxuPY/QjFYqCWbJg3Ryx5SSMMDuwemPWtfSIpbBLrUL1/K8wJEg3H5ucZIP1/Cs/Upbm21IzwQnbM4QvHzvOOAfc1jB6tI1ktEyfRIJv7Ra1TdCxjLgsQecjp6KfT2ouhdQyS+Zbb5nUhkjP4ZU9D6nNP028Md9bSK7eZgo0TAg556ZGeo6V2V7pkeo2mVYxufmUlfut+dRKpyy1LjC8dDz7SJAsfk3UYw0mEYv1f+6x7EY/Gtc6hHo9yT5qqqqSysM55/r29arXcl1pWsKstorXDKFkiHMV0nsSOD/KpDaR6nOWFhHp8MbBjERudwCMHIyAPYU5WbvLYUbrRbmjPqn9sSLLKcWkK7/KUZPmdgSeMj0p1vriDS/tUkEIjgYqWDkBlzjcMj3rRWMQwERRp5SllKhQA2e/+ea5TULtfLkiR/JtkOfKWMt5gJyx3DO3nPasoRU9LFyk46mtpstldTXF1Es8TKA7vISQVweVXp271A0Ui6o8c+ZIZ/nJJOQcDjj+VSeVHNo4bS/tELSKzCPcF3sR94n1Pr/Kk0u7uGlWFozHJsKs0m1gXXG729Oa0S3aJfZnlvxc1NbjWIrKbZIkaCINu+4xIJJPrjArjrC0NnJG0TRNbMxR2TnkcjPp+ta/xHkMPja7tJYvPLORtt3KjdgndyOev6UltNLEiteSZsJlyYfLBVGAKjdjGOR39K9OlZRVjgqXuy87266a0VnNHa3k5WNVaYu0jA8hnA+Uc/d/WpdI0q8uY0SIXE0s5wggcEkDtgnAAIPr+VVNNtWgt3ngZTeWymQIfmJQ5y27jDenX1NTaX4jfR44LnS3EIlkAlWSbLSBTn5u4+oqnezsSrdTRibTYN32tZVjmZ4HiSXEnmgAAnpgbsmhNVsYbKN5FkaASpFdrEFjVgpOACM7iep+nvVS5nF1C+dPSLUZI2mkkueSylyw256gjPPervh7TjewX0cGmGS68oS4kIhRRnBCqcg4JGOlQ7JXkUr3sjbjnvUklbTredtKuWWTY9unzHqqM2fmAAyMHI4rqvCSf2frMUF9boIbhmTcpJ/eNghtvbGCMj8a5TTml8O28lrHdRx30ygukiBlU425Usev5V6D4C8zVJGZ50cQ/NNAr4wezKM8Ag+vWuLEu0X2OugryXc9EtpJHbYiBSvHmDuoPr64+tSWsctu1xK8zMjuXAAGRk8fyq1aW/wBntI4EGY41Cjdz8uPeqMk7/bI7VI2ZCCrGMgeWMHr3HbpXlNWPQWpeuMDbKy7cgKSWA4pkzSLEpjEar02OOPwqrZ210l/CyysbQR7Sjgdhx+PXkfrWrNEkibHGVznHTpTSb1B6GTBbpLef6R5bzxMQu4BuOzDsPoKi1W0aRZXghljdVIjeM4ycY6DqBUhnlj1ryp9qQlcRsGH5E9cmov3tuqqb+eZJiVA+TcDnqGxz9PamkJshs3zZyWUBmkutoLmUksD6k9AePwzRTrq0eXTp53keSUcOofaJFHGG+tFU43FdnwDDdCLCJtZxzu34yDV1GE1sFdUYFsF+h5PSs57ONIQ67t3b0HtVrSLtkHlmQ+QXAfHbnr9a99Sd9Tx5JdCVoJLaJpEiYKrbHkHIpkcTHfcSq22Q7RhTk/StXWZSss1taEzRSKuBnr3yfWqc++DdNNM4L4IG04A9T6DpVka2IHdoYfIeNlTPAPVuneoXuALd0CuzAbQQMDr3qnqWpgjbgEjoeoqtaXamYhZNpHIz0NZuqr2TNFSk1ex0QvvNsFUAJJHnq2O3XH0qgbyUBYLhGGBkA/LnPc1cgvcXMcjJEgdNrMcc9skfjVURRXF9KsMm6MdGQYB9MA9R7Vbb0sSl3JIvIeVfKVQed2ew9q1IfDt3Mi/YZYtoJcYJDD05HXNZFzZXFnh2jYRNgjHA/wA+1dboerlNJ2wPIZR94M/KD2GO2KS10YnpqjD8yfS4TFPCy3ZfLtMp6Y6E9xzUkbRtC0ogVXY5cMRzjn5e4zmui1a4n1TTo4pLUNCAGWUcuw9WPrx/9asaVWtXkSDbdBkAR4+DjjOR6+/tVIm5o2NtbmdJZklR+QrMN2wY6Dnpz196lldoJmWMowUDlAM+o2kfrVCzvbmORPte6GVGK7AmQR/nFaOo3ESjzlj8sIAAVxg89OPWi4j1NbXUfFfhGG5dlNyqjYBjEmOvPv0rEOrSWmUurKaNUXayFSAW7nP4Ctv4Sa7by2U+myyYullMi9gyn0+ldxc29m8hFzbRsG+XcyZHPrXmSrezk4SWh3qnzpSTOZ8BahHb6ZdzzsUhmm3IrkAknqcenSutg+zzFjEwkAHXg9a80jjtFa/OogCRZyrI7f6sA8BQexAFdJ4DeKNNSC8WccqmNt3Qkcge1Z14bzRpSltFmxqek2V3+7mjZWB3LLEcEHGOvfjtVnT7FdIsnCIZo41OwoPmb2NB1HzJCsVu2xujuMAe+KntLmWZTvYdcDaP1rn53azNlBXujA0eX+0oZYJZ1l8xiOQMqw5z7emKuXsd1bWLJqKLcWe3ZvjO0x+hZcdv7w/KtF7a3sGn1ERRghCWITk45rLt7/U54DcT3CRbhuEapkL7HjmrvfVbE2to9x2m3tvciF9UgimVW2RXgTB9Pm9PTNdnbmPyV2FcAcYINcjb2K6hAxtGS3v4yTJBz5L5/iA9Dnr+dRRzRQGSOd306dGwYWYhWGeqnv8AhUySk7opOyszS8VXNrNAI/M2yDOxsfxe1Zov2+wRO3DyAKZ5M7UPQZx06/jQv2V5DNG8R4yNwz82cHI9D6VUlngknaIpgjJIK4yR2H/6uauKWxMm1qPciAzubi5neErmVsKOuM4/piqV1crd2DQafArPyr7mGSM8gD+Fu/PPNZ+uTwWU7qjSujRriNRhiQ24g+nQDIB9qYFv7Y3E4dYLSUYIVCMsfXPIOOCfpXRGGlzBy1sdgssVzoUn2FDLJGGjCOpjOQDx+GTWc1leWdkt1a7SbbcEhUA545VcY5znJNQXFteXVtBiNbGNsFYjku+TgZIORgZPv3pNTvILfw3crcytauodGMeSSQeSB0weDxUR0dl1Zbd1qeK+Ib6SPxZJfgfaJnzKomTIA5yhGPcYpm24sQtxaSF7d1DSRmLCb/vAANnkc13fwjsxrV7fXt4WkgiAEMb8ZweOfYYr0Xxd4RsLvTpJ4QYLkDDGIiMNjjjCnn6da7JYmEJ8jOWNCU48yPFW0nTzePKL+SNLgBo3B3CMsMlWGP72R17+lReJNP8AsWoxNCbUb4g7Mh3ozY7D9SOMVHq1le6CqyXUVwHLF45ON4kzyM4yfw9a6W11B9Q0+FrLTrK7Sc7JNPht9z7QuWbfksCfY5FbOVtUZKN9zk7WW6lgmuZvNupEiWBZGkxsTgDII4A5HtxWheSR6fqMK2kUZjH30S4aTgHJ3ZHBGO9VZdJuraMX0VkYrC4LxqXGRGOBwT1IBGKsGG3sr8m5NxeW6sFMm3Zlehwc5zzkZFO/YVu5p2ZbWIYrSW4Ry07TI5X5juH3T7Aj2HtXvPgXTLjTNEtljTz5HTLGc/cU9gQOmB3rx1oLZ9RSbTxY2kCIs0JVyZIhk7QwHUnAyCP0zXsGgi8n1C4vb67DLJHFshiIRgMZyVBI7469K8zGyvFLY78JG0rncIxgGS0mAuFjXnI7fjmmi3SCWURx7g2HIZsfr2qlBdSTXMayYR93yhG++F9fbnitUY3iRskMuCMZGa81ane9AlYyytHDOI3UAsuASM96Ylxtk8oIfmJ2/MPm7/hT1kgRsnYHOASep9M0x/LLbg4LOwDAkgfhVXJsZuraZDdm5WOSZZplwNrH5ScDPsBUdxBb2UVsr3EkE6xlYzHlzkc9AOf/AK9a8qJEJHRR5rHkADnHrUU3kELO21JguAc4I4p3AypFkuLOGWWTzbov+7VF2g8c8H26+9FWbaC1uZXViTNGQy7WBwPUfXvRVITPhi5060XUHRJPMh8vh0+7nH+FVo9JYcwYmQEMBnHPvzxSafcBNvmqGbOTnsB1q1DdKZvK+aNVzIoHHP8AhX0KPFd0Nu7dpdjR7i+05bp+vpWRqt6LaBY0YPHjGSO/51o6pqsZXyYnKyAEE9vpXJTB72QruHAPLHGKmpOy03KpQu/e2KLu0km/5uvFWHtgI4WVm2vwTtxz3pqwNEASSD7dhVtrcBIykhYS/dyRwf6VyRjfc7JSStYq+WVBMcgKjjPQit7w4AZsbsQsMMOcsfwqLSoJYUP7o+TMGiYnBzge4yPrUFrN/Zt3lSwjJ+U+nP8AOtYLlakzGcudOKO21Ror/Rn81FHkIGXaOOTjcw9ccZrI0zel3BOzsqHKA7cdP0zTbySZ7VS7BmIzuQDkYzj8MdKt28jDT3R2lMbquFKhAPXOf8munS5y7I6mGeewjiSWV2jwDJH/AHBk8dODz0rmdQlt40gjgZIrxZcmQHARRnII96LNr+VZwkwLRjDLKPmUAZHPc4p+gaWl693eXziWOMYLscLkjvn09O9DegJWJUt1nYyB8yIOTuyM989Oav2RV1MTznC5KlhwDjoB1PWq8RG2a6dIoEcLGiB9pOBwxHvkVNDFKqlXUlA6ncTgdcnvnFO4mallaTfbla1kMALYjcOV2HjOT612uka9f2GUnmluInG0NIQdh9cnt3rlLa5SCQxyQqMsDHJyATz82T1/KrtxLI8iFZzHHMQXkIBAI/xOKxqQjPdGkJuOzOskv7O/kje9ghMxUFXcIc/T1HBrorZkkWIOCpx8o24UAdx2ridPEUkMe6E3EjIA4PVMcgA+/XFdh4Ph895lJaaCFgOfvISOF/nXn14qMbo7KLbep0NrCZk+QsQemewpb9f7P0+5nUsvlruGOdx9D/Ko769ljmNvZlEOccjJ9z7CsrXJtQ+zoHLS274BePhkPG3OeCK44xu0jqk7Jl2Y38Fibico9mUJmhxg7T1weuarxiTTYdksDyQ7cpOqbg69tx7eh+lS2lrquoWK2l5FBFbEASSK5JZf9kY4z3J9al1GBpdTezmDG1ijVkhB4YY6/oeaq/Rit1LGlWdy0F3dxP5U8kDJHg5wex/TrWJcaNbXtkZT5wuo858yQlgw/vA5B5rVMclkFbTpWV8gCM/MvfIYf1qpe6iZZ/8ASdJDzH5PMjkABP8APFEZSveISivtGv4ZhhutLX7RbQiZGKSFFwCwql41gt/ssEVmsKXInUllO0gc5yR/jVHT0vngbZeyW9shJCRADBPqTyafaJDBJKzzeZt4kMjFiPUDPJoT5ZXuFrqxp6V4dtrqzEmoZkkZMOWPT3HpWM4mn0tW2mZYpNy7m271DdWx14FK8ko3x5dYFwyrvJUp2yOp4zV6C7LKFjaHBXcH4+UZ+6OePx9KrmktWLlTMe2s5dS1BJyn2eGIB4yWKkg9R79hzgiuQ+KHiEWU2nQ2vzzREsI5Ysj0xjoRnPH0rvtQvksI5nnAijhXcHZs7j2B9M14L4l1S48VeLEmsIHLyuAsavnaRwAD/nrXVQvJ8z2Rz1rRVludt8OdZm0ezje8gSZ5pD5WV/drITkqQOjDjmuu1bxYblre31K2hlt1AaQqw3op/jAHX0P8uah07w39s0m3tLmzaSRJFkCKAPKYnDEt0fp1IrqNM8JRafNI8NwiW0qELb7BhG74br25+vapqVaPNd7jhTqWstjzvxVeQaxaRQXjSh0AFrKi7YpWGcnI7bSeneuc006lpcrx2crQsshmkj8lim3oRu5PIJz0Ga9quPDkcek/ZmKvty8b8qFbkcZPA5ryzxJqU88tnbz6tOjLtWdmJ2qCxAxjOAAOf96t6NWM1yxWhlVpuOrZi2UWo3NzI9isrwxkOwU5RCCdoBOc5x0xzjFa3iO11P8AtSI+IktWdl3uC3lmRcKApA6EdM461kTgxzTPYypJbhijvAu1gmc+vX68c1rm4t9TmgkXT7l0hG3Bk3EgfeZiR16HA6d63d20zFWtY9D8M+HrjTtHtYdTOnxNcny4jJGCyjrnI9ORXVeGvD9t4d0tQk32kPJvdY8PyOCAfXrXI+BZE1mymneUXt7Gcw28hKFMDbgMAcde/BzXdaPYpbW7iW8Dz3QD7B93cP7pGP8AIzXjYmck3Fs9ShFWTSL0isGiltj5SqfmVl3kcf4VqWt0I7SAsv7wjAVFIycZ7+1Z0dwmnWqy3LKSW2u5wQoI79OBxVq3mnijRbyWMiRcxAAbemc1yo6Wi0J4GJkg+dl+856j6fhmrLmPap+VscdBnPb3rm9cu4baze68oQrgjPmYyc8cDk9OuOO9Vp/EFvJHDBBbu8k0YZXGGEZGPvkdOo/OqSbRLsjr/s6PaNAh2EjB6nHr/Wse9srtPntkh+RTtCnaWPYZz06ZzU2oIs9iHtWkRlbjYfmBzk85qycNFuRUEjgY3sc/Q9KrcnVGfYXNuI1gDlLmMfPGF+bknjPbmiqer30cFvMbnfa9zujBMnP58YHP86KtJvZCbS3Pz4fV2MgaNSgxg/59abPq8r71VcKemeoqNYjJAW2DavUqv6VSI3DcCM9xXqucl1OONOD6GjaxT3YLYPlsdpc8/NjpXQXVrpn9ixjBW9gU+ZGUwJMnu2fQ1jeHtTNoWh8tXLfcO3JDVe1GU3T3EbxeQUAySQAGz6enXpWsLct+pjUTUrbIoTLLFHE+YXMgwpH8IHH4Vv6aLO5aFbm3jS1ZNpPmkbHP8fr1rmpX2YgkaMleAyn9asWCyRyBgF2buVdiM/WiMtRSjobs0D6XEYZZoHhYBmkGeAff14rmLx/NKurDygdoPp/9etHU2mmgkkYITD8rANnI+noPWsiST9xgbUBOdgX+tFSXQdKPU6LTXlurWP5wPLBBYjHyn/JFalmsc6ygLzjmNe+Opqn4YR0sHk3KeQRGDjIxjPTmnXgkWJIGX54/niYHqvO5T69e/pW0W1FMwklzNI25LO0njaKArDbo4DyKW3S57Y7jNVFt2kUskwZclXB4UY4yB0OKWB5ZrhI/LUQyx4QsoHUZAJHfj9anvbaFZFlmkJj3gYRM+2DnoeM+hptojU1dMkgv4hGFS4uEHlygKWByMDb7+1eleH/h3FhZtVmYk4PkQ/Kvtk9TWV8KdBhd31GdVdIn/dMAAHb+9x1AzivWM4A59q83E4mSlyQZ3UKEWuaSKdtoOlQxFEsINp9Uyfzqlqng3T7r97ag21ygJQjBXPup69q3gRzUsZBHT2Fcka01qmdLpxejR5FqsN9pU7WcoEc2AOF4cf3hWh4B1o6ZqMkN5uC3Bw7FvlyOAR7c11PxAtBLpqXa53wBgoBx97Az05xXlV1FcpIwkVfLXId95Ut6ADrjvXowtiKdmcMr0Z3R7hqenfbJVnt5vKuVGQ2MqfqKhXTL26GLy4i2q2coP6H/AOvXlGj+NdYsEWBCl1G3yqkjZdWHofQ+9b7fEmV7SRJbLZKAATGS4/E4GAa4pYWstNzqWIpNXPT7TdACiMTFGNoDdao6pFb6hOhdlRojt3hwGx3H/wBavJpvFOq3BjhDGyib5TJg/N6AE9+taVrf6akklvJbxyy5xgHc+e+OfqaPqk463H9ZjLQ9IttHtZRvaeWRcY++fz/+vUF/o8NrAzJf3UQxuUAqSePUisrRb0QxG4lMqWsSksSdoXHasi68SfbJHcOGtomIZj/F6DHTA7+tZwp1G7FynBK5atGuLi6j2z3QtZRwzMuT0wMbfxqS90q605o3t71riJ32v5wA2dw2R/nkVjadqN1NfxvArlMHy48AkKB1x6Z6V0zXs1nZtJc+UiDJETtjKjqxPTPtWk+aDIhyzVzG1iSdYVFmzTOUIG3j5c8k8+tV0d9M0xpZHmeZ8bgy7gx4wMd+c1n22ryaj4glmt7eSK0aPdGhG1C46n3NaUt5E0aLKAFI3PnjAAySD6df1rWzjaLRndO7R59448W3WoyjToIgqbsuiAhn7DPsKX4T6feNfyzx5RoH3IFTO5j1BH0wK4jVXkvtVllLxncf3QXjgngDH1710nhEazpupWbaYLiN5QWAZdwkwcEEds4wa65RtBxjoc6l7ycj6LupLhbQ+VbKzjChC3yknH69eas6ZrUcsYS4MZkjdlkCZbZg4AOO9ZHhbWH1iw3RRC2vFdldHJ2nHUg9DiopdGSGSQ2vliYcuz5Dt3y3pzXhu0W4y0Z6q1Scdjrb63S40+eCV2dnBUkjrnsBxxXh+saHcI3m2T21xOjOQoG8BGI+c5444HXtXsmnyR6hap5RKSQAZ2k5UHqD9as3+mNfWBTbBD1UIqBl8s/wt+PpWlDEuk7EVaCqI8Ik8IahDLBqX2RmtblJdq/xA4746D3rc8NeDr+DTrbzWP2WW4EiBv8AVqMfMCDySenbNd9/wj39k6HNEkzOWBYRyMQpXPIQ9U/D2qdFktdJsrjYjW6kebCGEuxSMEgHliCM/nXRPGykrIxjhYp3ZRXwbp+lpLJaSzxLNKnnQxsQp54xheucYHGK7BDZqVg2qwUmUbnyynpkD165FZunXcSafFPbSyPA674VYbmJ/HpnHfpWjYr51t5hlijkO0L8nIJ6KSep7dq4Z1JS+JnZGEY/COtLmG41A2s6K6mMloXIfH+0V9D/APWp+kaY8EnmXEjkRKyxxKxITJzj6AcCpXNyrKzRRltuGO0D14B/pVi2nAmlikHkhgNjjqeOe2CPep5ug+UzLrztSsryx020jlwdizXGNmT1Udwax9D0KTSYJrOW3aaQ3GX6LHIpHv8Awjnv+VdTE8lkk5nnjMERDptj5K459ieO1W5Y2nsGRJwglU8uuSAe3PtWiqO3KiHFXucTrOrxaex0/wCx4UgCOMEgKR1bjoeR9cVp2msDUbiDTG3GZUWSSfHyqh9DnB6Cl1PTLe1jlJDPJ5RitzwQpPb196yPsB07RYjfWk/2j7ylQrMHJ/DHf61ScWvMTTuausS3d1eMslt9osIodxMoUASbsDk+2CQe1FWLpbPWdFl82BzFuVmAO3zcYwcd/p7UVcWurJkvI+AbfkmFMKOoPXH+c1Rul8uTYuADjPA54oor1p7HDT+IqOx8wsMKc/w8VdS5kuYvKkPKgENj0BoorKD1sbzS5blq3sEnSFy5HmNgj0PrTpHdNSmtA5ZTldzc8jv+lFFbtWSscqbk2n0uNniL2vnBsdAFxwPWsuZsyEHJA45ooqKhtR6ndaY4g0+OKRRJESu4Z2knHByKq6rLMdOkmMp2eYAUHG5vUn+lFFdMtInEtZGrpTmDSmGAwO7g9M464q5YeTeXssFxboVgRZAVJGT6jniiiqa0RK3Z7T8NyG0KNVG0RNtH5116EhVIJ+aiivBrr95I9Wk/dRCbgrdiPH8PXP8An1rQUkdKKKyW5p0OR+IGoyLaLYqMLOyguDyBmvOI288XPnNJIluqZVmHzgnp0469aKK9fDK1NWPOrtubuR6rDHHbtdQJ5ZbDqv8Acyf14HWqWmSSNLgSOBKoJ5zjIoorrWxz9TQ0q2a+meJ5nUIw565JGc13fhPw3F9n8xbmYPJ8zMQCScA9aKK8/FzlHRHbhoRk9S749iktdJtbFbiUx3EgRznaQoBJAx0ziuInC27QWzDehO4H7pGBgdOvWiinhNaaFiPjZ3PhOBJJbyVRsKgINo5AU+vvmn+NBELNlEKkSRMTu5xjniiiuS/786F/CMrQrhsW9qgClI1ZJDyVAOMe/U1m+Oh9lt7yZMFmk8kDaMKO+KKK6I6VrIylrTZyfhLw7HdC5up5g5EoidTEPmG4dD2r1jwvpItNU+wyS+fYJAAsLpzliCSWzmiis8ZOSbReGhHRkL6QtpqckNpPJAs8plURgARlenBzkc810v2Y6fDLewysztMizIwBWTLAZ9jzmiiuGrJtq5104pXsX4LiO1tRIkHAmEeN3XJxnp71vxEpKiZY7vlyT65/woornZqU9agjksCNibd6R7WGRgnFZ+mafELkyXOJQWCKijy1Ur1YBe5ooq07EslhljsteubOJJDHHEJEDOMDrxjHTj170zxBctFdRpgfNNCpKEoWJBbLY60UU0tUDdrnUxM8PkKWDCUZ6YwcZNS3DBQqBVy52AkZ2574/Ciil1sPomZ2p5EN3G0khiRQcAgE9O+PepraV7by4y7yI0YbDEcfpRRUpjexg6zBLDcytHcyIspETheNwKnn689RV2+0zzrART3U7rEPl5AyV/vcc59KKK1ei0JtqQaxH/xJmEDCAgBVMagbT0BA/GiiinFmcz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a human mesothelioma cell showing abundant microvilli arising from the cell surface (Mag 10,500x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Giuseppe G Pietra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5603=[""].join("\n");
var outline_f5_30_5603=null;
var title_f5_30_5604="Solar lentigines face";
var content_f5_30_5604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Solar lentigines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5604=[""].join("\n");
var outline_f5_30_5604=null;
var title_f5_30_5605="Deschamp carrier in use";
var content_f5_30_5605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Deschamp aneurysm ligature carrier",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The instrument is shown piercing an exposed sacrospinous ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5605=[""].join("\n");
var outline_f5_30_5605=null;
var title_f5_30_5606="Rufinamide: Drug information";
var content_f5_30_5606=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rufinamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18517?source=see_link\">",
"    see \"Rufinamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/12/29893?source=see_link\">",
"    see \"Rufinamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6802947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Banzel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13245578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Banzel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6819388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Triazole Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6819467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Lennox-Gastaut (adjunctive):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Initial: 400-800 mg/day in 2 equally divided doses; increase dose by 400-800 mg/day every other day to a maximum dose of 3200 mg/day in 2 equally divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;30 kg: Initial: 100 mg twice daily; increase dose by 5 mg/kg/day every 2 weeks until satisfactory control (maximum dose: 1300 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;30 kg: Initial: 200 mg twice daily; increase dose by 5 mg/kg/day every 2 weeks until satisfactory control (maximum dose: 30-50 kg: 1800 mg/day; 50.1-70 kg: 2400 mg/day; &ge;70.1 kg: 3200 mg/day).",
"     <b>",
"      Note:",
"     </b>",
"     Dose was increased as frequently as every other day in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant medications:",
"     </b>",
"     Valproate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Initial rufinamide dose should be &lt;400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: Initial rufinamide dose should be less than the initial daily recommended dosage; however, a specific dosage recommendation is not included in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6819466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/12/29893?source=see_link\">",
"      see \"Rufinamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Lennox-Gastaut (adjunctive):",
"     </b>",
"     Children &ge;4 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Initial: 10 mg/kg/day in 2 equally divided doses; increase dose by ~10 mg/kg every other day to a target dose of 45 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     3200 mg/day (whichever is lower) in 2 equally divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;30 kg: Initial: 100 mg twice daily; increase dose by 5 mg/kg/day every 2 weeks until satisfactory control (maximum dose: 1300 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;30 kg: Initial: 200 mg twice daily; increase dose by 5 mg/kg/day every 2 weeks until satisfactory control (maximum dose: 30-50 kg: 1800 mg/day; 50.1-70 kg: 2400 mg/day; &ge;70.1 kg: 3200 mg/day).",
"     <b>",
"      Note:",
"     </b>",
"     Dose was increased as frequently as every other day in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant medications:",
"     </b>",
"     Valproate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Initial rufinamide dose should be &lt;10 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: Initial rufinamide dose should be less than the initial daily recommended dosage; however, a specific dosage recommendation is not included in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6819468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6819469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Hemodialysis: No specific guidelines available; consider dosage adjustment for loss of drug.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6819470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate impairment: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment: Use in severe impairment has not been studied and is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6819489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banzel&reg;: 40 mg/mL (460 mL) [dye free, gluten free; contains propylene glycol; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banzel&reg;: 200 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13245860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Banzel&trade;: 100 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6819386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088564.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088564.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6819471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food. Tablets may be swallowed whole, split in half, or crushed. Oral suspension should be administered using the provided adapter and oral syringe; shake well before every administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6819390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the treatment of generalized seizures of Lennox-Gastaut syndrome",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6819401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: QT shortening (46% to 65%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (16% to 27%), somnolence (11% to 24%), dizziness (3% to 19%), fatigue (9% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (5% to 17%), nausea (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Ataxia (4% to 5%), seizure (children 5%), status epilepticus (&le;4%), aggression (children 3%), anxiety (adults 3%), attention disturbance (children 3%), hyperactivity (children 3%), vertigo (adults 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (children 4%), pruritus (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased (&ge;1% to 5%), abdominal pain (3%), constipation (adults 3%), dyspepsia (adults 3%), appetite increased (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (&le;4%), anemia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (adults 6%), back pain (adults 3%), gait disturbance (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Diplopia (4% to 9%), blurred vision (adults 6%), nystagmus (adults 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Otitis media (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Pollakiuria (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (children 5%), bronchitis (children 3%), sinusitis (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (children 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Atrioventricular block (first degree), bundle branch block (right), dysuria, enuresis, hematuria; hypersensitivity (multiorgan; includes eosinophilia, facial edema, fever, hepatitis [severe], LFTs increased, rash, stupor, urticaria); incontinence, iron-deficiency anemia, lymphadenopathy, nephrolithiasis, neutropenia, nocturia, polyuria, thrombocytopenia, urinary incontinence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6819396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with familial short QT syndrome",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Family history of short QT syndrome; presence or history of short QT interval; hypersensitivity to rufinamide, triazole derivatives, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6819397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered cardiac conduction: Has been associated with shortening of the QT interval. Use caution in patients receiving concurrent medications that shorten the QT interval. Contraindicated in patients with familial short-QT syndrome. Canadian labeling also contraindicates use in patients with a family history of short QT syndrome or presence or history of short QT interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: Use has been associated with CNS-related adverse events, most significant of these were cognitive symptoms (including somnolence or fatigue) and coordination abnormalities (including ataxia, dizziness, and gait disturbances). Caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal, multiorgan hypersensitivity reactions have been reported with some antiepileptic drugs, including rufinamide; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Rash: Closely monitor any patient who develops a rash; instruct patients to report any rash associated with fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate impairment; use in not recommended in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contraceptive failure: Concurrent use with hormonal contraceptives may lead to contraceptive failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Reducing dose by ~25% every two days was effective in trials.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Rufinamide. Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving divalproex. In patients receiving rufinamide, initiate divalproex at a low dose and titrate based on clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethinyl Estradiol: Rufinamide may decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norethindrone: Rufinamide may decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Rufinamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Rufinamide. Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6819432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food increases the absorption of rufinamide. Management: Take with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Evening primrose may decrease seizure threshold. Management: Avoid evening primrose.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6819391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6819392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were seen in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed. Hormonal contraceptives may be less effective with concurrent rufinamide use; additional forms of nonhormonal contraceptives should be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to rufinamide during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6819394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6819395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk is unknown, but may be expected. Breast-feeding is not recommended by the manufacturer due to the potential for adverse effects in the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6819486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Banzel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (460 mL): $748.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Banzel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $672.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (120): $1345.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6819487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure (frequency and duration); serum levels of concurrent anticonvulsants; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Inovelon (AT, CH, CZ, DE, DK, EE, FR, GB, GR, HN, IE, IL, IT, KP, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6819435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A triazole-derivative antiepileptic whose exact mechanism is unknown.",
"     <i>",
"      In vitro",
"     </i>",
"     , it prolongs the inactive state of the sodium channels, thereby limiting repetitive firing of sodium-dependent action potentials mediating anticonvulsant effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6819437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Slow; extensive &ge;85%; increased with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~50 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 34%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively via carboxylesterase-mediated hydrolysis of the carboxylamide group to CGP 47292 (inactive metabolite); weak inhibitor of CYP2E1 and weak inducer of CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Extent decreased with increased dose; oral tablets and oral suspension are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (85%, ~66% as CGP 47292, &lt;2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Deeks ED and Scott LJ, &ldquo;Rufinamide,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2006, 20(9):751-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/30/5606/abstract-text/16953653/pubmed\" id=\"16953653\" target=\"_blank\">",
"        16953653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser T, Kluger G, Sachdeo R, et al, &ldquo;Rufinamide for Generalized Seizures Associated With Lennox-Gastaut Syndrome,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2008, 70(21):1950-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/30/5606/abstract-text/18401024/pubmed\" id=\"18401024\" target=\"_blank\">",
"        18401024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perucca E, Cloyd J, Critchley D, et al, &ldquo;Rufinamide: Clinical Pharmacokinetics and Concentration-Response Relationships in Patients With Epilepsy,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2008, 49(7):1123-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/30/5606/abstract-text/18503564/pubmed\" id=\"18503564\" target=\"_blank\">",
"        18503564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9518 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5606=[""].join("\n");
var outline_f5_30_5606=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802947\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13245578\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819388\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819467\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819466\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819468\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819469\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819470\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819489\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13245860\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819386\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874987\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819471\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819390\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819401\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819396\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819397\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300017\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833946\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819432\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819391\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819392\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819394\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819395\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819486\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321875\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819487\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961942\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819435\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819437\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18517?source=related_link\">",
"      Rufinamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/12/29893?source=related_link\">",
"      Rufinamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_30_5607="Office spirometry";
var content_f5_30_5607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Office spirometry",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5607/contributors\">",
"     Paul L Enright, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5607/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5607/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/30/5607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is used to measure forced expiratory flow rates and volumes. It is the most commonly used pulmonary function test and is useful in the evaluation of patients with respiratory symptoms (eg, dyspnea, cough, wheeze) or risk factors for respiratory disease (eg, smoking, occupational exposures, family history).",
"   </p>",
"   <p>",
"    In the office setting, spirometry is typically used to detect, confirm, and monitor obstructive airway diseases (eg, asthma, COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In this setting, the clinician must be knowledgeable about issues related to equipment, performance of the forced expiratory maneuver, and interpretation of the data to obtain reliable and clinically useful information [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. International guidelines for performance of office spirometry have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The performance of spirometry in the office setting will be reviewed here. More general issues related to pulmonary function tests, the interpretation of flow volume loops, and the technique of bronchoprovocation testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of spirometers manufactured since 1990 are accurate, although some flow-sensing office spirometers can produce falsely high results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The National Lung Health Education Program (NLHEP) has published guidelines for office spirometers and has a list of features (eg, graphic output) that should be available [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid cross-contamination between patients when using permanent flow sensors, it is preferable to employ single use disposable flow sensors that practically eliminate the risk of inhalational cross contamination. Disposable one-way mouthpieces may also be used; otherwise, patients should be instructed not to inhale from the spirometer prior to forced exhalation maneuvers. Volume sensing spirometers maintain accuracy over many years, but are more difficult to clean and are rarely used for office spirometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     QUALITY CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Office spirometers should accurately measure the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), forced expiratory volume in six seconds (FEV",
"    <sub>",
"     6",
"    </sub>",
"    ), and forced vital capacity (FVC) and also provide quality checks and error messages.",
"   </p>",
"   <p>",
"    In addition to internal calibration performed by the device, daily calibration checks with a three liter syringe are recommended, since permanent flow sensors can become clogged with secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ]. When performing a calibration check, the three liter syringe should be discharged into the spirometer three times. The volumes read by the machine should be within 3.5 percent of three liters. If the spirometer reading remains outside these limits after replacing the flow sensor, the device should be removed from use until checked by the manufacturer.",
"   </p>",
"   <p>",
"    It is also essential that the nurse or technician enter correct values for age, height, and gender, as these values are used to generate the appropriate predicted values for the individual patient. Height should be measured with shoes off, preferably using a stadiometer, rather than relying on the patient's stated height. Percent predicted values that are higher or lower than expected are a clue that an incorrect age or height value may have been entered. Waist circumference should also be measured because abdominal obesity is a common cause of a mildly low FVC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are usually seated during spirometry, unless otherwise noted. Nose clips or manual occlusion of the nares help to prevent air leakage through the nasal passages, although spirometry can be performed without nasal occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ]. The deep inhalation should occur before the mouthpiece is placed in the mouth. Immediately after the deep inhalation, the mouthpiece is placed just inside the mouth between the teeth. The lips should be sealed tightly around the mouthpiece to prevent air leakage during maximal forced exhalation. Exhalation should last at least 6 seconds.",
"   </p>",
"   <p>",
"    The patient is allowed to rest for several seconds and the procedure is repeated. Usually, three maneuvers are performed, although additional tests may be needed if one or more of the curves are unacceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COACHING THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important task of the nurse or technician is to obtain maximal, reproducible efforts from the patient.",
"   </p>",
"   <p>",
"    Even with the use of accurate instruments, office spirometry results may be misleading if the patient's efforts are submaximal. Unlike most other medical tests in which the patient remains passive, accurate spirometry results require significant exertion on the part of the patient.",
"   </p>",
"   <p>",
"    The technician must instruct and encourage the patient to perform the breathing maneuvers in three phases (",
"    <a class=\"graphic graphic_figure graphicRef55460 \" href=\"UTD.htm?31/19/32062\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phase 1: Coach the patient to take as deep a breath as possible",
"     </li>",
"     <li>",
"      Phase 2: Loudly prompt the patient to blast out the air into the spirometer",
"     </li>",
"     <li>",
"      Phase 3: Encourage the patient to continue exhaling for at least six seconds (3 seconds for children)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADEQUACY OF TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adequate test usually requires three acceptable and reproducible FVC maneuvers. The clinician and technician must learn to recognize the patterns of acceptable and unacceptable efforts, since poorly performed maneuvers often mimic disease patterns. Detection of poorly performed maneuvers requires direct inspection of both flow-volume curves and volume-time spirograms (",
"    <a class=\"graphic graphic_figure graphicRef57832 \" href=\"UTD.htm?43/13/44253\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/12,15\">",
"     12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An acceptable maneuver requires a sharp peak in the flow curve and an expiratory duration greater than six seconds (",
"    <a class=\"graphic graphic_figure graphicRef65057 \" href=\"UTD.htm?14/27/14782\">",
"     figure 3",
"    </a>",
"    ). Two or three acceptable maneuvers should be available for analysis.",
"   </p>",
"   <p>",
"    Reproducibility is determined by comparing the FVC values of the maneuvers. The two highest values for FVC should be within 0.15 L of each other [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Similarly, the two highest values for FEV",
"    <sub>",
"     1",
"    </sub>",
"    should be within 0.15 L of each other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All tracings from the forced expiratory maneuvers should be examined for acceptability and reproducibility, according to the criteria mentioned above. The study should then be classified as normal, borderline, or abnormal, the latter showing either an obstructive or a restrictive pattern (",
"    <a class=\"graphic graphic_figure graphicRef65057 \" href=\"UTD.htm?14/27/14782\">",
"     figure 3",
"    </a>",
"    ). The severity of any obstructive impairment is then assessed (",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Forced expiratory volume in one second'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Forced vital capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced vital capacity (FVC) (also known as the forced expiratory volume) is the maximal volume of air exhaled with a maximally forced effort from a position of full inspiration and is expressed in liters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ]. The highest FVC from the three acceptable forced expiratory maneuvers is used for interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FVC may be reduced by suboptimal patient effort, airflow limitation, restriction (eg, from lung parenchymal, pleural, or thoracic cage disease), or a combination of these. An approach to the interpretation of abnormal values is provided in the figures (",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/12\">",
"     12",
"    </a>",
"    ]. The specific values assigned to mild, moderate, and severe disease vary among the different guidelines; we have included in the figure the ones that we find most consistent for predicting the degree of impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. In general, a moderately or severely low FVC needs further evaluation with full pulmonary function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The slow vital capacity (SVC) is the maximal volume of air exhaled after a maximal inspiration, but without a forced effort. The SVC is rarely measured outside of hospital-based pulmonary function labs. For normal subjects, the slow and forced vital capacities are very close, whereas patients with airflow limitation tend to have a much lower FVC than SVC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Spirometry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Forced expiratory volume in 6 seconds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced expiratory volume in 6 seconds (FEV",
"    <sub>",
"     6",
"    </sub>",
"    ) is sometimes used as a surrogate for FVC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. The FEV",
"    <sub>",
"     6",
"    </sub>",
"    has the advantage of being more reproducible than the FVC and less physically demanding for the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Forced expiratory volume in one second",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) is the maximal volume of air exhaled in the first second of a forced exhalation that follows a full inspiration, expressed in liters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ]. The FEV",
"    <sub>",
"     1",
"    </sub>",
"    reflects the average flow rate during the first second of the FVC maneuver. The FEV",
"    <sub>",
"     1",
"    </sub>",
"    is the most important spirometric variable for assessment of the severity of airflow obstruction (",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 4",
"    </a>",
"    ). The highest FEV",
"    <sub>",
"     1",
"    </sub>",
"    from the three acceptable forced expiratory maneuvers is used for interpretation, even if it does not come from the maneuver with the highest FVC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with asthma, the FEV",
"    <sub>",
"     1",
"    </sub>",
"    declines in direct and linear proportion with clinical worsening of airways obstruction, and it increases with successful treatment of airways obstruction. The FEV",
"    <sub>",
"     1",
"    </sub>",
"    should be used for determining the degree of obstruction (mild, moderate, or severe) and for serial comparisons when following patients with asthma or COPD.",
"   </p>",
"   <p>",
"    The measured FEV",
"    <sub>",
"     1",
"    </sub>",
"    is usually expressed as a percent of the predicted value for determination of normality (",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 4",
"    </a>",
"    ). The reference values from the NHANES III study (recently expanded to pre-school children) are recommended for use throughout North America [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. The lower limit of normal FEV",
"    <sub>",
"     1",
"    </sub>",
"    is more accurately defined by the fifth percentile of healthy never-smokers, instead of the traditional 80 percent of predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a rough guideline, the predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    for a 50 year-old of average height is about 4.0 L for a man and 3.0 L for a woman. When predicted values have not been calculated, patients with severe COPD generally have an FEV",
"    <sub>",
"     1",
"    </sub>",
"    less than one liter, while those with moderate COPD have an FEV",
"    <sub>",
"     1",
"    </sub>",
"    between 1.0 and 1.5 liters. It is unusual for patients with COPD to have dyspnea due to airflow obstruction when the FEV",
"    <sub>",
"     1",
"    </sub>",
"    is greater than 50 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=see_link\">",
"     \"Reference values for pulmonary function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ratio of FEV1/FVC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio is the fraction of the forced vital capacity that can be exhaled in the first second. It is the most important parameter for detecting airflow limitation in diseases like asthma and COPD (",
"    <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"     figure 4",
"    </a>",
"    ). However, once it has been determined that a patient has airways obstruction, the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio is not useful for gauging severity of disease, since the FVC also tends to decrease with increasing obstruction. The FEV",
"    <sub>",
"     1",
"    </sub>",
"    , not the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio, should be used to monitor patients with asthma or COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When FVC maneuvers are routinely stopped after six seconds, the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FEV",
"     <sub>",
"      6",
"     </sub>",
"    </span>",
"    should replace the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/22\">",
"     22",
"    </a>",
"    ]. The advantages of the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FEV",
"     <sub>",
"      6",
"     </sub>",
"    </span>",
"    include less frustration by the patient and technician trying to achieve an end-of-test plateau, less chance of syncope, shorter testing time, and better repeatability, without loss of sensitivity or specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/18,23-25\">",
"     18,23-25",
"    </a>",
"    ]. The appropriate lower limit of normal for",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FEV",
"     <sub>",
"      6",
"     </sub>",
"    </span>",
"    from NHANES III should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/19,26\">",
"     19,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fifth percentile lower limit of normal (LLN) reduces the misclassification rate for detecting airway obstruction in comparison to a commonly accepted fixed threshold of 0.70 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/20,27-29\">",
"     20,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other flow measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition from normal function to moderate airflow obstruction is generally gradual. Physiologists have searched for a test that is more sensitive than the FEV",
"    <sub>",
"     1",
"    </sub>",
"    for detection of airflow obstruction in its early stages. None has proven to be as reliable as the index obtained by dividing the FEV",
"    <sub>",
"     1",
"    </sub>",
"    by the FVC. The forced expiratory flow between 25 and 75 percent of the FVC (also known as FEF25-75 or maximal mid-expiratory flow rate) should not be used to detect &ldquo;small airways disease&rdquo; in adults, due to poor reproducibility [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choosing the best values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Report the highest FVC and the highest FEV",
"    <sub>",
"     1",
"    </sub>",
"    from three spirometric maneuvers, even if they are derived from different maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Flow-volume loops",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow-volume loop is a plot of inspiratory and expiratory flow (on the Y-axis) against volume (on the X-axis) during the performance of maximally forced inspiratory and expiratory maneuvers. Changes in the contour of the loop can detect upper airway obstruction. The analysis of flow-volume loops is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Office spirometry has some important limitations, even when all of the above described quality measures are employed. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spirometry has limited ability to detect mild or early COPD in smokers, since airway obstruction predicts only about 10 percent of the variability in the subsequent decline in lung function in patients with COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal spirometry results have little if any value in prompting smokers to quit [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a patient with asthma, normal airflow at the time of office visits does not exclude serious airflow obstruction at other times.",
"     </li>",
"     <li>",
"      Patients with early interstitial lung disease or sarcoidosis may have normal spirometry and need further testing of gas transfer with a DLCO",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exercise oximetry to identify the cause of dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Misclassification rates due to suboptimal spirometry performance or interpretation are relatively high in the office setting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. Among eight general practices, rates for successfully meeting American Thoracic Society (ATS) quality standards were below 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/6\">",
"     6",
"    </a>",
"    ]. Therefore, continuous quality review and feedback to nurses and technologists performing office spirometry are necessary and results should be verified by repeat testing in a Pulmonary Function Test (PFT) laboratory when important clinical decisions will be made based on the results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is a low risk procedure and has few side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/12\">",
"     12",
"    </a>",
"    ]. During the test, some patients may experience dizziness. The forced expiratory maneuver causes an increase in the pressure in the chest, abdomen, head, and eyes. In general, patients who have recently (eg, less than six weeks) had abdominal, intracranial, or eye surgery or a pneumothorax should not perform spirometry, although data are limited.",
"   </p>",
"   <p>",
"    Spirometry requires exertion and should be avoided in patients with unstable angina or a recent myocardial infarction.",
"   </p>",
"   <p>",
"    Rarely, performance of a forced expiratory maneuver will precipitate acute bronchoconstriction. This seems more likely to occur when a patient's asthma or COPD is poorly controlled. Treatment includes administering inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    and supplemental oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Office spirometry is also useful for monitoring control of asthma The National Asthma Education and Prevention Program advises the following frequencies for spirometry testing when caring for patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the time of initial assessment",
"     </li>",
"     <li>",
"      After treatment is initiated and symptoms and peak flow have stabilized",
"     </li>",
"     <li>",
"      During periods of progressive or prolonged loss of asthma control",
"     </li>",
"     <li>",
"      At least every one to two years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with COPD, repeat spirometry is advised whenever there is a substantial increase in symptoms or decrease in exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5607/abstract/4,38,39\">",
"     4,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POST-BRONCHODILATOR SPIROMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have evidence of airflow limitation on baseline spirometry, and no prior diagnosis of asthma or COPD, post-bronchodilator spirometry may be useful. If post-bronchodilator spirometry is normal, COPD is ruled out. The assessment of bronchodilator responses in patients with asthma-like symptoms is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Bronchodilator responses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spirometry is used to detect and monitor obstructive airway disease in patients with respiratory symptoms and risk factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Office spirometers should accurately measure the forced expiratory volume in 1 second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) and either forced vital capacity (FVC) or forced expiratory volume in 6 seconds (FEV",
"      <sub>",
"       6",
"      </sub>",
"      ). Calibration checks should be performed daily with a three liter syringe.",
"     </li>",
"     <li>",
"      Since poorly performed maneuvers often mimic disease patterns, the clinician and technician must learn to recognize the patterns of unacceptable efforts (",
"      <a class=\"graphic graphic_figure graphicRef57832 \" href=\"UTD.htm?43/13/44253\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Quality control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An acceptable maneuver requires a sharp rise in the flow volume curve to the peak flow and an expiratory duration greater than six seconds. At least three good quality maneuvers should be performed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Quality control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Report the highest FVC and the highest FEV",
"      <sub>",
"       1",
"      </sub>",
"      from three spirometric maneuvers, even if they are derived from different maneuvers. The fifth percentile lower limit of normal (LLN) for",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      is preferred over the commonly accepted fixed threshold of 0.70, as it reduces the misclassification rate for detecting airway obstruction. &nbsp;(See",
"      <a class=\"local\" href=\"#H13\">",
"       'Choosing the best values'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Ratio of FEV1/FVC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduction of the",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      and the FEV",
"      <sub>",
"       1",
"      </sub>",
"      suggests airway obstruction (",
"      <a class=\"graphic graphic_figure graphicRef72469 \" href=\"UTD.htm?16/26/16814\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FEV",
"       <sub>",
"        6",
"       </sub>",
"      </span>",
"      is preferred over the",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      when the FVC maneuvers are routinely stopped after six seconds. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ratio of FEV1/FVC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The FEV",
"      <sub>",
"       1",
"      </sub>",
"      should be used for determination of the degree of impairment and for serial comparisons.",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio is not useful for gauging severity of disease, since the FVC also tends to decrease with increasing obstruction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Misclassification rates due to spirometry misinterpretation are relatively high in the primary care setting; therefore, results should be verified by formal testing in a PFT laboratory when important clinical decisions will be made based on the results. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/1\">",
"      Enright P, Quanjer P. Don't diagnose mild COPD without confirming airway obstruction after an inhaled bronchodilator. COPD 2007; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/2\">",
"      Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest 2007; 132:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/3\">",
"      Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006; 129:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/4\">",
"      Lin K, Watkins B, Johnson T, et al. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/5\">",
"      Enright, PL, Studnicka, M, Zielinski, J. Spirometry to detect and manage COPD and asthma in the primary care setting. Eur Respir Mon 2005; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/6\">",
"      Walters JA, Hansen EC, Johns DP, et al. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD. Thorax 2008; 63:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/7\">",
"      Lusuardi M, De Benedetto F, Paggiaro P, et al. A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. Chest 2006; 129:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/8\">",
"      Levy ML, Quanjer PH, Booker R, et al. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG)1 document, in association with the Association for Respiratory Technology &amp; Physiology (ARTP)2 and Education for Health3 1 www.gpiag.org 2 www.artp.org 3 www.educationforhealth.org.uk. Prim Care Respir J 2009; 18:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/9\">",
"      Townsend MC, Hankinson JL, Lindesmith LA, et al. Is my lung function really that good? Flow-type spirometer problems that elevate test results. Chest 2004; 125:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/10\">",
"      Liistro G, Vanwelde C, Vincken W, et al. Technical and functional assessment of 10 office spirometers: A multicenter comparative study. Chest 2006; 130:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/11\">",
"      Schermer TR, Verweij EH, Cretier R, et al. Accuracy and precision of desktop spirometers in general practices. Respiration 2012; 83:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/12\">",
"      Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/13\">",
"      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/14\">",
"      Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179:509.",
"     </a>",
"    </li>",
"    <li>",
"     Enright PL. Office spirometry. In: Atlas of office procedures, 1999. Vol 2, p.299.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/16\">",
"      Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/17\">",
"      Vandevoorde J, Verbanck S, Schuermans D, et al. Forced vital capacity and forced expiratory volume in six seconds as predictors of reduced total lung capacity. Eur Respir J 2008; 31:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/18\">",
"      Swanney MP, Jensen RL, Crichton DA, et al. FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000; 162:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/19\">",
"      Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008; 177:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/20\">",
"      Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011; 139:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/21\">",
"      O'Donnell DE. Breathlessness in patients with chronic airflow limitation. Mechanisms and management. Chest 1994; 106:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/22\">",
"      Jing JY, Huang TC, Cui W, et al. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest 2009; 135:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/23\">",
"      Jensen RL, Crapo RO, Enright P. A statistical rationale for the use of forced expired volume in 6 s. Chest 2006; 130:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/24\">",
"      Bellia V, Sorino C, Catalano F, et al. Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax 2008; 63:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/25\">",
"      Vollmer WM, G&iacute;slason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009; 34:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/26\">",
"      Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/27\">",
"      Hnizdo E, Glindmeyer HW, Petsonk EL, et al. Case definitions for chronic obstructive pulmonary disease. COPD 2006; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/28\">",
"      Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/29\">",
"      Garc&iacute;a-Rio F, Soriano JB, Miravitlles M, et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011; 139:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/30\">",
"      Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/31\">",
"      Buffels J, Degryse J, Decramer M, Heyrman J. Spirometry and smoking cessation advice in general practice: a randomised clinical trial. Respir Med 2006; 100:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/32\">",
"      Enright P. Does screening for COPD by primary care physicians have the potential to cause more harm than good? Chest 2006; 129:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/33\">",
"      Boros PW, Enright PL, Quanjer PH, et al. Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J 2010; 36:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/34\">",
"      Joo MJ, Au DH, Fitzgibbon ML, et al. Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med 2011; 26:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/35\">",
"      Poels PJ, Schermer TR, Akkermans RP, et al. General practitioners' needs for ongoing support for the interpretation of spirometry tests. Eur J Gen Pract 2007; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/36\">",
"      Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008; 32:945.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on August 12, 2009).",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Updated 2008. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from file://www.goldcopd.org (Accessed on August 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5607/abstract/39\">",
"      Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147:633.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6968 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5607=[""].join("\n");
var outline_f5_30_5607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      QUALITY CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COACHING THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADEQUACY OF TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Forced vital capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Forced expiratory volume in 6 seconds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Forced expiratory volume in one second",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ratio of FEV1/FVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other flow measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choosing the best values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RISKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POST-BRONCHODILATOR SPIROMETRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6968|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/19/32062\" title=\"figure 1\">",
"      Spirometry technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/13/44253\" title=\"figure 2\">",
"      Curves from unacceptable FVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14782\" title=\"figure 3\">",
"      Flow volume curve variations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/26/16814\" title=\"figure 4\">",
"      Severity obstructive dz",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=related_link\">",
"      Reference values for pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_30_5608="Overview of preterm labor and birth";
var content_f5_30_5608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of preterm labor and birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5608/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5608/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5608/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/30/5608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm birth refers to a delivery that occurs before",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation. It may or may not be preceded by preterm labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32275940\">",
"    <span class=\"h1\">",
"     PRETERM BIRTH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6273581\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtypes of preterm birth are variably defined.",
"   </p>",
"   <p>",
"    By gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate preterm: 32 to &lt;37 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Late preterm:",
"      <span class=\"nowrap\">",
"       34",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       36",
"       <sup>",
"        6/7ths",
"       </sup>",
"      </span>",
"      weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Very preterm: 28 to &lt;32 weeks",
"     </li>",
"     <li>",
"      Extremely preterm: &lt;28 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birth weight (LBW): &lt;2500 grams",
"     </li>",
"     <li>",
"      Very low birth weight (VLBW): &lt;1500 grams",
"     </li>",
"     <li>",
"      Extremely low birth weight (ELBW): &lt;1000 grams",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As spontaneous or provider-initiated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 70 to 80 percent of preterm births occur spontaneously and are related to preterm labor, which accounts for 40 to 50 percent of preterm births, or preterm premature rupture of membranes (PPROM), which accounts for 20 to 30 percent of preterm births. The remaining 20 to 30 percent of preterm births are medically indicated because of maternal or fetal issues (eg, preeclampsia, placenta previa, abruptio placenta, fetal growth restriction, multiple gestation) (",
"      <a class=\"graphic graphic_table graphicRef74561 \" href=\"UTD.htm?7/40/7819\">",
"       table 1",
"      </a>",
"      ). Complications of pregnancy can lead to both spontaneous and provider-initiated preterm births.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using a combination of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Global Alliance to Prevent Prematurity and Stillbirth has recently proposed an alternative classification system [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/3\">",
"       3",
"      </a>",
"      ]. Under this system, preterm birth is categorized according to the clinical phenotype consisting of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One or more conditions of the mother, placenta or fetus",
"     </li>",
"     <li>",
"      Presence or absence of signs of parturition",
"     </li>",
"     <li>",
"      Pathway to delivery (spontaneous or caregiver initiated).",
"      <br/>",
"      <br/>",
"      This system does not force any preterm birth into a predefined phenotype (spontaneous or indicated) and allows relevant maternal, fetal, and placental conditions to become part of the phenotype. Under this newly proposed classification system, preterm birth would include women delivered between",
"      <span class=\"nowrap\">",
"       37",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       38",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of pregnancy, which would increase the US rate of prematurity to about 28 percent, which is more than twice what is typically reported (about 12 percent for births",
"      <span class=\"nowrap\">",
"       &lt;37",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm birth is the leading direct cause of neonatal death (death in the first 28 days of life). It is responsible for 27 percent of neonatal deaths worldwide, comprising over one million deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The risk of neonatal mortality decreases as gestational age at birth increases, but the relationship is nonlinear (",
"    <a class=\"graphic graphic_figure graphicRef54530 \" href=\"UTD.htm?24/45/25310\">",
"     figure 1",
"    </a>",
"    ). The burden of preterm birth includes neonatal morbidity and long-term sequelae, including neurodevelopmental deficits (eg, cerebral palsy, impaired learning, visual disorders) and an increased risk of chronic disease in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21096?source=see_link&amp;anchor=H21#H21\">",
"     \"Perinatal mortality\", section on 'Causes of infant death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The percentage of newborns delivered at very low birthweight (less than 1500 grams) has declined only minimally from 1.46 percent in 2008 to 1.45 percent in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/6\">",
"     6",
"    </a>",
"    ]. Therefore, preterm birth continues to be a major determinant of short- and long-term morbidity in infants and children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13814?source=see_link\">",
"     \"Long-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, preterm birth is the second most common cause of-death (after pneumonia) in children younger than 5 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few countries provide reliable national preterm birth prevalence data. Worldwide, the preterm birth rate is estimated to be about 11 percent (range 5 percent [parts of Europe] to 18 percent [parts of Africa]), and about 15 million children are born preterm each year (range 12 to 18 million) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Of these preterm births, 84 percent occurred at 32 to 36 weeks, 10 percent occurred at 28 to &lt;32 weeks, and 5 percent occurred at &lt;28 weeks.",
"   </p>",
"   <p>",
"    In the United States in 2010, 11.99 percent of births occurred preterm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/6\">",
"     6",
"    </a>",
"    ]. The preterm births were distributed as follows: 34 to 36 weeks (8.49 percent), 32 to 33 weeks (1.53 percent), less than 32 weeks (1.97 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2271872\">",
"    <span class=\"h2\">",
"     Pathogenesis of spontaneous preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and laboratory evidence suggest that a number of pathogenic processes can lead to a final common pathway that results in spontaneous preterm labor and delivery. The four primary processes are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activation of the maternal or fetal hypothalamic-pituitary-adrenal axis associated with either maternal anxiety and depression or fetal stress",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Decidual hemorrhage",
"     </li>",
"     <li>",
"      Pathological uterine distention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These processes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The new proposed phenotypic classification of preterm birth aims to take into consideration pathophysiologic events occurring with the mother, placental or fetal compartment. Therefore, the pathophysiologic mechanisms of preterm birth are likely to expand to include factors such as functional progesterone withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/8\">",
"     8",
"    </a>",
"    ], and failure of physiologic transformation of the spiral arteries, which is associated with both abruption and fetal stress due to uteroplacental vascular insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidemiology and risk factors for spontaneous preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm birth rates in the United States are highest among women of &lt;20 and &gt;35 years of age and among non-Hispanic black mothers, followed by American Indian or Alaskan Natives, Hispanics, non-Hispanic whites, and Asian or Pacific Islanders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous risk factors for spontaneous preterm birth have been reported (",
"    <a class=\"graphic graphic_table graphicRef68992 \" href=\"UTD.htm?27/48/28428\">",
"     table 2",
"    </a>",
"    ). Causal associations between most of these risk factors and preterm birth have been difficult to prove because (1) many preterm births occur among women with no risk factors, (2) some obstetrical complications resulting in preterm birth require cofactors to exert their effect, making the chain of causality difficult to document, and (3) an adequate animal model for study of preterm birth does not exist. Risk factors for preterm birth are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32276031\">",
"    <span class=\"h1\">",
"     PRETERM LABOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of true labor, contractions and cervical change, are the same whether labor occurs preterm or at term. The following are early signs and symptoms of labor; however, they are non-specific and can be present for several hours in women who do not exhibit cervical change:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Menstrual-like cramping",
"     </li>",
"     <li>",
"      Mild, irregular contractions",
"     </li>",
"     <li>",
"      Low back ache",
"     </li>",
"     <li>",
"      Pressure sensation in the vagina",
"     </li>",
"     <li>",
"      Vaginal discharge of mucus, which may be clear, pink, or slightly bloody (ie, mucus plug, bloody show)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uterine contractions are the sine qua non of labor, but mild irregular contractions are a normal finding at all stages of pregnancy, thereby adding to the challenge of distinguishing true labor (contractions that result in cervical change) from false labor (contractions that do not result in cervical change). Increasing frequency of contractions suggests true labor; however, the frequency of contractions may increase transiently and increases with gestational age, the number of fetuses, and at night. Although many investigators have tried, no one has been able to identify a threshold contraction frequency that effectively identifies women who will progress to true labor. True labor is more likely when an increased frequency of contractions is accompanied by increased intensity and duration of contractions.",
"   </p>",
"   <p>",
"    Cervical changes on physical examination that precede or accompany true labor include dilation, effacement, softening, and movement to a more anterior position. A short or a dilated cervix may be the first clinical manifestation of a parturition process triggered by decidual activation or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/12\">",
"     12",
"    </a>",
"    ]. The rate of cervical change distinguishes cervical ripening, which occurs over days to weeks, from true labor, which occurs over minutes to hours.",
"   </p>",
"   <p>",
"    Transvaginal ultrasound is the most reliable method for measuring cervical length. In symptomatic and asymptomatic preterm patients, sonographic identification of a short cervix (&lt;30 mm) is predictive of an increased risk of preterm labor and birth; the shorter the cervix, the higher the risk of preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15376999\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of preterm labor is generally based upon clinical criteria of regular painful uterine contractions accompanied by cervical change (dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effacement). The presence of vaginal bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ruptured membranes increases diagnostic certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/13\">",
"     13",
"    </a>",
"    ]. Because the clinical criteria for preterm labor are poorly predictive of the diagnosis until labor is well established, over-diagnosis is common.",
"   </p>",
"   <p>",
"    Specific clinical criteria, which were initially developed to select subjects in research settings, include persistent uterine contractions (4 every 20 minutes or 8 every 60 minutes) with documented cervical change or cervical effacement of at least 80 percent or cervical dilatation greater than 2 cm. Women who do not meet these criteria are diagnosed with false labor; these women typically go on to have a late preterm or term delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Approach to the patient with suspected preterm labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preterm labor is one of the most common reasons for hospitalization of pregnant women, identifying women with preterm contractions who will deliver preterm is an inexact process. In one systematic review, approximately 30 percent of preterm labors spontaneously resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/15\">",
"     15",
"    </a>",
"    ]. In another systematic review, only 13 percent of women presenting at &lt;34 weeks of gestation with explicit contraction criteria for preterm labor delivered within one week [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/16\">",
"     16",
"    </a>",
"    ]. Others have reported 50 percent of patients hospitalized for preterm labor deliver at term [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2272458\">",
"    <span class=\"h3\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our initial evaluation of women with suspected preterm labor includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal vital signs (temperature, blood pressure, heart rate, respiratory rate), as well as fetal heart rate and contraction",
"      <span class=\"nowrap\">",
"       frequency/duration/intensity.",
"      </span>",
"      Uterine contractions are evaluated continuously using a contraction monitor, palpation, and the patient&rsquo;s subjective assessment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H18#H18\">",
"       \"Management of normal labor and delivery\", section on 'Uterine contractions'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Review of the patient&rsquo;s past and present obstetrical and medical history, and assessment of gestational age.",
"     </li>",
"     <li>",
"      Evaluation for signs and symptoms of preterm labor (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above) and presence of risk factors for preterm birth (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology and risk factors for spontaneous preterm birth'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Examination of the uterus to assess firmness, tenderness, fetal size, and fetal position.",
"     </li>",
"     <li>",
"      Speculum examination using a wet non-lubricated speculum, with particular attention to cervical dilation and effacement. In addition:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence and amount of uterine bleeding should be assessed. Bleeding from abruptio placenta or placenta previa can trigger preterm labor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"       \"Placental abruption: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=see_link\">",
"       \"Clinical features, diagnosis, and course of placenta previa\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The status of the fetal membranes, intact or ruptured, should be determined. Preterm premature rupture of membranes (PPROM) often precedes or occurs during preterm labor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H4#H4\">",
"       \"Preterm premature rupture of membranes\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We obtain a swab for fetal fibronectin (fFN). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link&amp;anchor=H3#H3\">",
"       \"Fetal fibronectin for prediction of preterm labor and delivery\", section on 'Sample collection and results'",
"      </a>",
"      .) However, we only send the swab to the laboratory for fFN determination if the cervical length is 20 to 30 mm (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Triage based upon cervical length'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      A rectovaginal group B streptococcal culture should be performed if not done within the previous five weeks; antibiotic prophylaxis depends on the results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H14#H14\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Approach to threatened preterm delivery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening for gonorrhea and chlamydia is indicated for women at increased risk of these infections; testing for bacterial vaginosis and trichomoniasis is indicated in women symptomatic for these infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"       \"Approach to women with symptoms of vaginitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44807?source=see_link&amp;anchor=H21417087#H21417087\">",
"       \"Prenatal care (after initial prenatal assessment)\", section on 'Sexually transmitted disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrasound examination. Digital cervical examination has limited reproducibility between examiners, especially when changes are not pronounced; therefore, we also use transvaginal ultrasound to evaluate the cervix in all pregnancies &lt;34 weeks when the diagnosis of labor is uncertain. This information is useful for supporting the diagnosis of preterm labor. Short cervical length before 32 weeks of gestation is predictive of preterm birth in all populations studied, including asymptomatic women, and is a more sensitive indicator of a patient's risk for preterm birth than cervical dilatation. A short cervix after 32 weeks is less predictive of preterm delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"       \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We also perform an obstetrical ultrasound examination to look for maternal and fetal anatomic abnormalities, confirm the fetal presentation, assess amniotic fluid volume, and estimate fetal weight. This information is useful for management of preterm labor and delivery, and counseling the patient regarding the potential causes and outcomes of preterm birth (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Triage based upon cervical length'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical dilation and effacement may be assessed by digital examination",
"      <strong>",
"       after",
"      </strong>",
"      placenta previa and PPROM have been excluded (by history and physical, laboratory, and ultrasound examinations, as indicated) and after swabs for fFN and rectovaginal Group B streptococcal (GBS) culture have been obtained and transvaginal ultrasound examination has been performed.",
"      <br/>",
"      <br/>",
"      When assessing cervical dilation and effacement in the second trimester, it is important to distinguish between patients whose membranes have hour-glassed (prolapsed) through a mildly dilated and effaced cervix (suggestive of cervical insufficiency) from those who are fully dilated and effaced as a result of advanced labor. Ultrasound imaging can distinguish between these two diagnoses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H89361408#H89361408\">",
"       \"Cervical insufficiency\", section on 'Physical examination reveals a dilated cervix and visible membranes before 24 weeks'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H7#H7\">",
"       \"Transvaginal cervical cerclage\", section on 'Replacement of prolapsed membranes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We obtain a urine culture, since asymptomatic bacteriuria is associated with an increased risk of preterm labor and birth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"       \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We perform drug testing in patients with risk factors for substance abuse, given the link between cocaine use and placental abruption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"       \"Overview of illicit drug use in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Triage based upon cervical length",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data from large randomized trials to help determine the optimal management of symptomatic women with suspected preterm labor and intact membranes. The approach described below reflects our paradigm based upon our experience and available data. As a general guideline, preterm birth is highly unlikely in symptomatic women if cervix length is &gt;30 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/13,20-22\">",
"     13,20-22",
"    </a>",
"    ], unless abruption is the cause of their symptoms, and most likely in those with cervical length &lt;15 to 20 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/13,16,20,23,24\">",
"     13,16,20,23,24",
"    </a>",
"    ]. In a pooled analysis including over 1000 singleton pregnancies presenting with threatened preterm labor, about 60 percent of all women with cervical length &le;15 mm delivered within 7 days, and 71 percent of women less than 34 weeks of gestation with cervical length &le;15 mm delivered within 7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/16\">",
"     16",
"    </a>",
"    ]. In another series, only 1 of 415 patients with cervical length &ge;16 mm delivered within 7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Cervical length &gt;30 mm",
"    </span>",
"    &nbsp;&mdash;&nbsp;These women are at",
"    <strong>",
"     low",
"    </strong>",
"    risk of preterm birth, regardless of fFN result, so we do not send their swabs for fFN testing to the laboratory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link&amp;anchor=H6#H6\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\", section on 'Cervical length combined with fFN'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We discharge the patients home after an observational period of four to six hours during which we confirm fetal well-being (eg, reactive nonstress test), exclude the presence of an acute precipitating event (eg, abruption or overt infection), and assure ourselves that the cervix is not progressively dilating or effacing.",
"   </p>",
"   <p>",
"    We arrange follow-up in one to two weeks and give the patient instructions to call if she experiences additional signs or symptoms of preterm labor, or has other pregnancy concerns (eg, bleeding, rupture of membranes, decreased fetal activity). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"     \"Patient information: Preterm labor (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Cervical length 20 to 30 mm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervical length 20 to 30 mm are at increased risk of preterm birth compared to women with longer cervical length, but most of these women do not deliver preterm. Therefore, for this subgroup of women, we send the swab for fFN testing. If the test is positive (fFN level greater than 50",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    we actively manage the pregnancy in an attempt to prevent morbidity associated with preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link&amp;anchor=H6#H6\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\", section on 'Cervical length combined with fFN'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Cervical length &lt;20 mm",
"    </span>",
"    &nbsp;&mdash;&nbsp;These women are at",
"    <strong>",
"     high",
"    </strong>",
"    risk of preterm birth regardless of the fFN result. Therefore, we do not send swabs for fFN testing to the laboratory and we actively manage the patient in an attempt to prevent morbidity associated with preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link&amp;anchor=H6#H6\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\", section on 'Cervical length combined with fFN'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We hospitalize women diagnosed with preterm labor &lt;34 weeks of gestation and initiate the following treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      to reduce neonatal morbidity and mortality associated with preterm birth (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tocolytic drugs for up to 48 hours to delay delivery so that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      given to the mother can achieve its maximum fetal effect (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"       \"Inhibition of acute preterm labor\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Antibiotics for GBS chemoprophylaxis, when appropriate (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H14#H14\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Approach to threatened preterm delivery'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Appropriate antibiotics to women with positive urine culture results (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"       \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      for pregnancies at 24 to 32 weeks of gestation. In utero exposure to magnesium sulfate provides neuroprotection against cerebral palsy and other types of severe motor dysfunction in offspring born preterm (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=see_link\">",
"       \"Neuroprotective effects of in utero exposure to magnesium sulfate\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preterm labor itself is not an indication for antibiotic prophylaxis or treatment in the absence of documented infection or GBS prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/26\">",
"     26",
"    </a>",
"    ]. There is no role for progesterone supplementation in the treatment of acute preterm labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H14419401#H14419401\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Acute preterm labor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of women after successful inhibition of preterm labor is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24135?source=see_link\">",
"     \"Management of pregnant women after inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3347779\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions with proven efficacy for prevention of preterm birth include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5608/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking cessation (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"       \"Smoking and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progesterone supplementation (in asymptomatic women with previous preterm birth or in asymptomatic women with no history of preterm birth but a short cervix in the current pregnancy) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoidance of induction of labor and scheduled cesarean delivery in the absence of medical indications (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H5#H5\">",
"       \"Principles of labor induction\", section on 'Elective induction at term'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H4#H4\">",
"       \"Cesarean delivery: Preoperative issues\", section on 'Indications and contraindications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduction of multiple gestation by limiting the number of embryo transfers in women undergoing assisted reproductive technology (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=see_link\">",
"       \"Strategies to control the rate of high order multiple gestation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerclage (in women with previous preterm birth and a short cervix in current pregnancy) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"       \"Cervical insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=see_link\">",
"       \"Patient information: Preterm labor (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=see_link\">",
"       \"Patient information: How to tell when labor starts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       \"Patient information: Preterm labor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of preterm labor is based on clinical criteria of regular painful uterine contractions accompanied by cervical dilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      effacement. (See",
"      <a class=\"local\" href=\"#H15376999\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound measurement of cervical length and laboratory analysis of cervicovaginal fetal fibronectin (fFN) level help to support or exclude the diagnosis (",
"      <a class=\"graphic graphic_algorithm graphicRef78336 \" href=\"UTD.htm?15/38/15983\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Triage based upon cervical length'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with suspected preterm labor, we administer tocolytic drugs for up to 48 hours, antibiotics for Group B streptococcal (GBS) chemoprophylaxis (when appropriate), and antenatal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      . Appropriate antibiotics are administered to women with positive urine culture results. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO, March of Dimes, Partnership for Maternal, Newborn &amp; Child Health, Save the Children. Born too soon: the global action report on preterm birth www.who.int/maternal_child_adolescent/documents/born_too_soon/en/ (Accessed on May 04, 2012).",
"    </li>",
"    <li>",
"     WHO Statistical Information System (WHOSIS). Low birthweight newborns. www.who.int/whosis/indicators/compendium/2008/2bwn/en/index.html (Accessed on April 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/3\">",
"      Villar J, Papageorghiou AT, Knight HE, et al. The preterm birth syndrome: a prototype phenotypic classification. Am J Obstet Gynecol 2012; 206:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/4\">",
"      Lawn JE, Gravett MG, Nunes TM, et al. Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth 2010; 10 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/5\">",
"      Mwaniki MK, Atieno M, Lawn JE, Newton CR. Long-term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. Lancet 2012; 379:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/6\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/7\">",
"      Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012; 379:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/8\">",
"      Zakar T, Mesiano S. How does progesterone relax the uterus in pregnancy? N Engl J Med 2011; 364:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/9\">",
"      McMaster-Fay RA. Failure of physiologic transformation of the spiral arteries of the uteroplacental circulation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2004; 191:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/10\">",
"      Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract Res Clin Obstet Gynaecol 2011; 25:313.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/nchs/vitalstats.htm (Accessed on April 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/12\">",
"      Iams JD, Cebrik D, Lynch C, et al. The rate of cervical change and the phenotype of spontaneous preterm birth. Am J Obstet Gynecol 2011; 205:130.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/13\">",
"      Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003; 101:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/14\">",
"      Chao TT, Bloom SL, Mitchell JS, et al. The diagnosis and natural history of false preterm labor. Obstet Gynecol 2011; 118:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/15\">",
"      King JF, Grant A, Keirse MJ, Chalmers I. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol 1988; 95:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/16\">",
"      Sotiriadis A, Papatheodorou S, Kavvadias A, Makrydimas G. Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. Ultrasound Obstet Gynecol 2010; 35:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/17\">",
"      Gazmararian JA, Petersen R, Jamieson DJ, et al. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol 2002; 100:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/18\">",
"      Scott CL, Chavez GF, Atrash HK, et al. Hospitalizations for severe complications of pregnancy, 1987-1992. Obstet Gynecol 1997; 90:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/19\">",
"      McPheeters ML, Miller WC, Hartmann KE, et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol 2005; 192:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/20\">",
"      Tsoi E, Fuchs IB, Rane S, et al. Sonographic measurement of cervical length in threatened preterm labor in singleton pregnancies with intact membranes. Ultrasound Obstet Gynecol 2005; 25:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/21\">",
"      Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007; 197:426.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/22\">",
"      Murakawa H, Utumi T, Hasegawa I, et al. Evaluation of threatened preterm delivery by transvaginal ultrasonographic measurement of cervical length. Obstet Gynecol 1993; 82:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/23\">",
"      Tsoi E, Akmal S, Rane S, et al. Ultrasound assessment of cervical length in threatened preterm labor. Ultrasound Obstet Gynecol 2003; 21:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/24\">",
"      Fuchs I, Tsoi E, Henrich W, et al. Sonographic measurement of cervical length in twin pregnancies in threatened preterm labor. Ultrasound Obstet Gynecol 2004; 23:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/25\">",
"      American College of Obstetricians and Gynecologists, Committee on Practice Bulletins&mdash;Obstetrics. ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol 2012; 119:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/26\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol 2011; 117:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5608/abstract/27\">",
"      Chang HH, Larson J, Blencowe H, et al. Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index. Lancet 2013; 381:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6798 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5608=[""].join("\n");
var outline_f5_30_5608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32275940\">",
"      PRETERM BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6273581\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2271872\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidemiology and risk factors for spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32276031\">",
"      PRETERM LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15376999\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Approach to the patient with suspected preterm labor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2272458\">",
"      - Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Triage based upon cervical length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cervical length &gt;30 mm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cervical length 20 to 30 mm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cervical length &lt;20 mm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3347779\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6798|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?15/38/15983\" title=\"algorithm 1\">",
"      Management of suspected preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6798|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/45/25310\" title=\"figure 1\">",
"      NNM by gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7819\" title=\"table 1\">",
"      Proportion of preterm birth by etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/48/28428\" title=\"table 2\">",
"      Risk factors for preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13814?source=related_link\">",
"      Long-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24135?source=related_link\">",
"      Management of pregnant women after inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=related_link\">",
"      Neuroprotective effects of in utero exposure to magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21096?source=related_link\">",
"      Perinatal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44807?source=related_link\">",
"      Prenatal care (after initial prenatal assessment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_30_5609="Dialysis-related amyloidosis";
var content_f5_30_5609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dialysis-related amyloidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5609/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/30/5609/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/30/5609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis-related amyloidosis (DRA) is a disorder caused by tissue deposition of beta2 microglobulin as amyloid fibrils [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The clearance of beta2 microglobulin, a component of the major histocompatibility complex that is present on cell surfaces, normally occurs by glomerular filtration with subsequent reabsorption and catabolism in proximal tubules. Clearance therefore declines in patients with reduced kidney function, leading to plasma accumulation and slow tissue deposition.",
"   </p>",
"   <p>",
"    The tissue deposition of amyloid detected histologically occurs much earlier than any clinical or radiographic manifestations of the illness. A prospective postmortem study found joint amyloid deposition in 21 percent in patients receiving hemodialysis for less than two years, 50 percent at four to seven years, 90 percent at seven to thirteen years, and 100 percent at more than thirteen years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/8\">",
"     8",
"    </a>",
"    ]. By comparison, some centers have reported the clinical prevalence of the disease as zero at five years, which increased to approximately 50 percent at twelve years and to almost 100 percent at twenty years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, such data were largely obtained during periods when hemodialysis was performed with low flux cellulose-derived dialysis membranes that were impermeable to beta2-microglobulin. Although little data are available, dialysis related amyloidosis is currently considered to be much less frequent than previously noted given that most hemodialysis is now performed with high flux dialyzer membranes or convective therapies associated with increased clearance of beta2-microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/7\">",
"     7",
"    </a>",
"    ]. These approaches are associated with increased clearance of beta2-microglobulin.",
"   </p>",
"   <p>",
"    However, even these more modern hemodialysis therapies can be associated with retention of beta2-microglobulin. The incidence in patients on peritoneal dialysis is even less clear since there are few patients who have been dialyzed for prolonged periods. Some observations suggest that peritoneal dialysis is associated with a similar risk as hemodialysis, a finding that would be expected since there is limited removal of beta2-microglobulin by peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of dialysis-related amyloidosis is presented in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to fragments of immunoglobulin light chains in primary amyloidosis and serum amyloid A in secondary amyloidosis, the amyloid protein in DRA is composed primarily of beta2-microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. The amyloid found in the bone cysts and synovial tissue in patients with DRA is similar to other forms of amyloid in its staining properties with Congo red and in exhibiting apple-green birefringence under polarized light. It has been proposed that beta2-microglobulin has a high affinity for collagen, an effect that could explain the predominance of joint and bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .) Beta2-microglobulin amyloid deposits contain a number of associated molecules (eg, glycosoaminoglycans, proteoglycans, Apo E) that appear to be involved in their formation and stabilization and in the sites of deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clearance of beta2-microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying the tissue deposition of beta2-microglobulin among patients with end-stage renal disease is the inability to adequately clear this substance, even with modern high flux hemodialysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    convective therapies. As an example, assuming steady beta2-microglobulin generation and a 70 kg anuric individual, net yearly beta2-microglobulin retention is 111, 97, 77, 53, and 51 grams with low flux conventional hemodialysis, high flux dialysis, short daily hemodialysis, nocturnal hemodialysis, and short daily hemofiltration, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/7\">",
"     7",
"    </a>",
"    ]. Despite these differences, predialysis plasma levels are similar in patients treated with high-flux hemodialysis and hemofiltration.",
"   </p>",
"   <p>",
"    There is limited clearance of beta2-microglobulin with peritoneal dialysis. In one study, for example, clearance was significantly higher with high flux hemodialysis versus peritoneal dialysis (29 versus 6",
"    <span class=\"nowrap\">",
"     liters/week",
"    </span>",
"    per 1.73 m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The persistence of even a minimal degree of residual glomerular filtration and renal function is sufficient to increase clearance and catabolism of beta2-microglobulin, thereby protecting against DRA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Hemodialysis membrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients dialyzed with low flux membranes have a somewhat higher plasma beta2-microglobulin concentration than patients dialyzed with more porous membranes. The more permeable membranes have an intrinsically greater rate of convective transport (although diffusion is limited by the size of the beta2-microglobulin molecule) and also may directly bind beta2-microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/13-18\">",
"     13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These characteristics may be important clinically. Although little data is available, dialysis related amyloidosis is currently considered to be much less frequent than previously noted given that most hemodialysis is now performed with high flux biocompatible dialyzer membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/7,19-21\">",
"     7,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One multicenter report found that in patients over age 60 at the start of dialysis, the likelihood of developing amyloid bone disease was five times higher with low flux membranes compared to high-flux membranes (",
"      <a class=\"graphic graphic_figure graphicRef68848 \" href=\"UTD.htm?34/62/35821\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study, 89 patients with end-stage renal disease maintained on regular hemodialysis for at least 10 years and treated with one type of dialysis membrane exclusively were divided into three groups: low-flux, bioincompatible cellulose, low-flux, intermediately biocompatible polysulphone or PMMA, or high-flux, highly biocompatible polysulphone or AN69 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/21\">",
"       21",
"      </a>",
"      ]. Clinical symptoms of DRA were most significant in the low-flux bioincompatible cellulose group and were the lowest in the high-flux highly biocompatible group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intradialytic beta2-microglobulin production",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is clear that elevated beta2-microglobulin levels in hemodialysis patients are due primarily to reduced renal clearance, the dialysis procedure itself may mildly stimulate intradialytic beta2-microglobulin production. Hemodialysis patients have enhanced production of beta2-microglobulin by peripheral blood monocytes grown in culture after dialysis with a cuprophane membrane, but not with the more biocompatible noncomplement-activating, polymethylmethacrylate membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/19\">",
"     19",
"    </a>",
"    ]. Two mechanisms may contribute to the bioincompatible membrane stimulation of beta2-microglobulin synthesis: contact of the cells with the membrane; and with activated late complement components [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/22\">",
"     22",
"    </a>",
"    ]. It is also possible that dialysate contaminated with endotoxin stimulates the release of beta2-microglobulin from leukocytes and monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of intradialytic generation of beta2-microglobulin in the pathogenesis of DRA and the role of bioincompatible versus biocompatible membranes remain unclear. Bioincompatible membranes are characterized by their propensity to cause an acute decrease in polymorphonuclear leukocytes and to activate the complement system. Thus, beta2-microglobulin production might be stimulated by circulating cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/24\">",
"     24",
"    </a>",
"    ]. If true, then low-level, subclinical inflammation may promote the development of DRA.",
"   </p>",
"   <p>",
"    The importance of membrane biocompatibility was directly addressed in a trial in which 159 new hemodialysis patients were prospectively randomly assigned to dialysis with either a low-flux biocompatible or low-flux bioincompatible membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/25\">",
"     25",
"    </a>",
"    ]. Plasma beta2-microglobulin levels rose over time in both groups (since the rate of production remains greater than the rate of removal) but the increment above baseline (24.8 to 27.8",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    was significantly less in patients treated with biocompatible membranes (2.6 versus 11.1",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"    This beneficial effect was independent of the influence of residual renal function and increased progressively over time. Another report noted fewer radiologic signs of DRA in patients treated with",
"    <span class=\"nowrap\">",
"     PAN/AN69",
"    </span>",
"    compared to cuprophane membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/20\">",
"     20",
"    </a>",
"    ]. Another report compared patients treated with a polyamide high-flux membrane and low-flux dialyzers; those on the high-flux membrane had lower beta2-microglobulin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/26\">",
"     26",
"    </a>",
"    ]. This difference was thought to be caused by less beta2-microglobulin release and better beta2-microglobulin clearance with high-flux dialyzers.",
"   </p>",
"   <p>",
"    However, there are reports and observational data suggesting that intradialytic generation of beta microglobulin is not a significant underlying factor in DRA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some studies, the prevalence of DRA was not higher in patients treated with cuprophane hemodialysis membranes compared to AN69 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum levels of beta2 microglobulin are similar in patients treated with peritoneal dialysis as with hemodialysis.",
"     </li>",
"     <li>",
"      DRA has developed in patients who have never undergone hemodialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of reactive inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid tissue deposit lesions are associated with a marked influx of activated macrophages expressing cytokines, such as interleukin-1, tumor necrosis factor-alpha, and transforming growth factor-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/29\">",
"     29",
"    </a>",
"    ]. These macrophages appear to be unable to adequately phagocytose deposited beta-2 microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, the destructive spondyloarthropathy may be mediated in part by amyloid deposition, an inability to adequately process such deposition, and reactive inflammation.",
"   </p>",
"   <p>",
"    The increase in inflammatory mediators may be related to blood-dialysis membrane interactions or endotoxin and other contaminants in dialysate water. In a study of 480 hemodialysis patients, dialyzer membrane (cellulose, synthetically modified cellulose, synthetic low-flux, and synthetic high-flux), water treatment, demographic, and laboratory features were analyzed for relationship with beta2-microglobuin-related bone cysts and carpal tunnel syndrome. The incidence of both manifestations of beta2-microglobulin disease declined after initiation of reverse osmosis for water treatment. High CRP was a risk factor, while higher albumin and residual GFR were associated with lower risk. The dialysis membrane used was not associated with manifestations of beta2-microglobulin deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta2-microglobulin may also cause bone destruction by directly stimulating formation of osteoclasts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/32\">",
"     32",
"    </a>",
"    ]. Residual GFR may also be an important factor in the development of beta2-microglobulin amyloidosis, along with age, dialysis vintage, and CRP levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Modification of beta2-microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycosylated beta2-microglobulin, a modified microglobulin resulting from the activity of 3-deoxyglucose, has been found in amyloid deposits, as so-called advanced glycation end products (AGEs) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/34\">",
"     34",
"    </a>",
"    ]. Since 3-deoxyglucose is present at increased levels in the serum of uremic and hemodialysis patients, the modification of beta2-microglobulin may occur more readily in renal failure. The presence of glycosylated beta2-microglobulin in amyloid deposits may further enhance the development of these lesions by both stimulating the secretion of cytokines and acting as a chemoattractant and an apoptosis-delaying agent for monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenic effects of glycosylated beta2-microglobulin may be prevented via the administration of aminoguanidine, an agent that inhibits advanced glycation. The potential utility of aminoguanidine in DRA was suggested by an in vitro study which incubated beta2-microglobulin and D-glucose in the presence or absence of the agent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/38\">",
"     38",
"    </a>",
"    ]. Aminoguanidine resulted in a significant inhibition of advanced glycation end products detected on beta2-microglobulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestations of DRA include carpal tunnel syndrome, bone cysts, spondyloarthropathy, pathologic fractures, and swollen painful joints, particularly in the form of scapulohumeral periarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/1-3,39\">",
"     1-3,39",
"    </a>",
"    ]. Symptoms related to carpal tunnel syndrome and shoulder pain are the two most common clinical features associated with DRA.",
"   </p>",
"   <p>",
"    These symptoms are a result of the preferential amyloid deposition in the bones, joints, and synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/40\">",
"     40",
"    </a>",
"    ]. However, DRA is a systemic disease since deposition also occurs in subcutaneous tissues and skin, and less frequently in rectal mucosa, liver, spleen, and blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/39,41-43\">",
"     39,41-43",
"    </a>",
"    ]. Unlike primary amyloidosis, visceral involvement in DRA rarely causes clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carpal tunnel syndrome is one of the most frequent presenting manifestations of DRA. Its predilection for hemodialysis patients has been recognized for a long time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/44\">",
"     44",
"    </a>",
"    ], with the average time to onset being approximately 8 to 10 years after the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/45\">",
"     45",
"    </a>",
"    ]. As previously mentioned, the prevalence of this disorder is time-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. However, other factors (such as direct compression and ischemia) may also contribute, since not all cases of carpal tunnel syndrome in hemodialysis patients are amyloid-positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2643?source=see_link\">",
"     \"Uremic mononeuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the need for carpal tunnel syndrome surgery was reported to be lower in patients treated with hemodiafiltration and hemofiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/46,47,49\">",
"     46,47,49",
"    </a>",
"    ], this has not been observed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/50\">",
"     50",
"    </a>",
"    ]. The weakness of these studies is the lack of consistent diagnostic criteria for the diagnosis of this complication and the lack of contemporaneous controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Scapulohumeral periarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shoulder is the most likely joint to cause symptoms in patients dialyzed for many years. DRA is just one of the disorders that can lead to chronic shoulder pain as the differential diagnosis also includes bursitis and rotator cuff tear. The amyloid deposits in DRA are found in synovial tissue and in the subacromial bursa [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effusive arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients dialyzed for longer than eight years may develop an effusive arthropathy, often in association with the carpal tunnel syndrome. The effusion is frequently bilateral, especially in the knees and shoulders. The aspirated fluid is serous with a low cell count, although the effusion may be bloody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Spondyloarthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondyloarthropathy due to deposits of amyloid material has been reported in the cervical region of the spine with consequent radiculopathy. These deposits can lead to spondyloarthropathy and radiculopathy.",
"   </p>",
"   <p>",
"    Cervical pain may be the first clinical clue to the presence of amyloid spondyloarthropathy. MRI is the most useful test to assess the extent of the lesions. The disease has a predilection for the lower cervical spine. Narrowed disk spaces and erosion of the vertebral margin are common, and subchondral sclerosis may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/52\">",
"     52",
"    </a>",
"    ]. The problem may be severe enough to lead to paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/53,54\">",
"     53,54",
"    </a>",
"    ] or, via infiltration of the extradural space, to cauda equina compression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone lesions of DRA are typically cystic, occurring at the ends of long bones. They may be mistakenly called \"brown tumors,\" as seen in some dialysis patients with severe hyperparathyroid bone disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .) The cystic lesions contain amyloid, enlarge with time, and may be associated with pathologic fractures of the carpal bones, fingers, femoral and humeral heads, acetabulum, tibial plateau, and distal radius.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common, gastrointestinal complications have also been described in DRA. The colon may be most frequently involved, possibly leading to malabsorption, colonic dilatation or perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Other sites of involvement include the tongue, esophagus, stomach and small intestine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=see_link\">",
"     \"Gastrointestinal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other sites of involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac, pulmonary, and cutaneous involvement with DRA have been rarely described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Beta2-microglobulin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma beta2-microglobulin concentration is increased in dialyzed patients, with a level ranging from 30 to 50",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    much higher than the normal value of 0.8 to 3.0",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/59\">",
"     59",
"    </a>",
"    ]. However, elevated beta2-microglobulin levels alone do not establish the diagnosis, since they may be seen in patients without",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    prior to) DRA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tissue histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amyloid found in the bone cysts and synovial tissue is similar to other forms of amyloid in its staining properties with Congo red and in exhibiting apple-green birefringence under polarized light. In contrast to fragments of immunoglobulin light chains in primary amyloidosis and serum amyloid A in secondary amyloidosis, the amyloid protein in DRA is composed primary of beta2-microglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a survey of some of the imaging modalities used and the characteristic findings in DRA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/56,60\">",
"     56,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Conventional radiography, which is frequently used for screening or initial diagnosis, reveals radiolucent lesions, or bone cysts, frequently with thin sclerotic margins. The lesions tend to enlarge and increase in number over time (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85529 \" href=\"UTD.htm?13/39/13936\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT and magnetic resonance imaging are particularly useful for detection of lesions too small to be seen with plain radiographs and for lesions of the nonaxial skeleton [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. One study found supraspinatus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subscapularis tendon thickening in chronic dialysis recipients as determined by MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/62\">",
"       62",
"      </a>",
"      ]. MRI and CT may also be useful for detection of soft tissue deposits. However, the administration of gadolinium during MR imaging has been strongly linked to an often severe disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in dialysis patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultrasonography may be of use in DRA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/63-66\">",
"       63-66",
"      </a>",
"      ]. It can detect increased rotator cuff thickness and a thickened synovial sheath of the long head of the biceps [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Scintigraphy with radiolabeled beta2-microglobulin, recombinant beta2-microglobulin, radiolabeled serum amyloid P component, and other radiopharmaceuticals have been utilized, with results affected by the specific labeled protein but have not been consistently useful [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/67-70\">",
"       67-70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DRA is usually suspected in the dialysis patient with characteristic clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic features. However, the tissue deposition of amyloid occurs much earlier than any such manifestation.",
"   </p>",
"   <p>",
"    The diagnosis of DRA is based upon the presence of typical clinical features supported by either documented tissue deposition of amyloid (via synovial biopsy or aspirate of joint effusions) or the characteristic radiographic picture of multiple bone cysts that enlarge over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As stated in the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, biopsy remains the \"gold standard\" for the diagnosis of beta2-microglobulin amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/5\">",
"     5",
"    </a>",
"    ]. Despite this, the diagnosis of DRA is usually clinical and relies upon the combination of typical clinical features plus characteristic radiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/7\">",
"     7",
"    </a>",
"    ]. Abdominal fat pad aspirates are not useful for the diagnosis of DRA. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgery and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most debilitating aspects of DRA are the carpal tunnel syndrome and the propensity to pathologic fractures from bone cysts in strategic locations (such as the femoral neck). Analgesics help with periarticular and bone pain.",
"   </p>",
"   <p>",
"    Since DRA is a progressive disease, early surgical correction of carpal tunnel syndrome is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/48\">",
"     48",
"    </a>",
"    ]. Other surgical interventions that may be beneficial include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthroscopic or open surgery of the shoulder with removal of synovium infiltrated by amyloid often provides dramatic pain relief [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Curettage and bone grafting of amyloid cysts in the femoral neck has been successful in relieving hip pain [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/72\">",
"       72",
"      </a>",
"      ]. The grafts were successfully incorporated into the bone defects.",
"     </li>",
"     <li>",
"      Replacement of a diseased joint with a prosthesis must be considered on an individual basis; when performed, this modality can relieve pain and restore lost mobility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Increased clearance of beta2-microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once DRA develops, there are few studies examining the relative efficacy of specific therapies. Most proposed interventions are based on studies showing increased beta2 clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Duration, frequency, and type of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altering the duration, frequency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    type of dialysis treatment are potentially important strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A four hour dialysis at a low blood flow rate (200",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      removes greater quantities of beta2-microglobulin than a short dialysis (two hours) at a high blood flow rate (400",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nocturnal hemodialysis (performed for eight hours, six nights per week at low blood and dialysate flow rates) is associated with significantly higher clearances of beta2-microglobulin (585 versus 127",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      and a greater reduction in plasma beta2-microglobulin concentrations (39 versus 21 percent) compared with conventional hemodialysis (performed for four hours, three times per week) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"       \"Technical aspects of nocturnal hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short daily hemodialysis also appears to be associated with enhanced middle molecule removal versus that observed with conventional hemodialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"       \"Short daily hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Significant removal of beta2-microglobulin occurs with hemofiltration and hemodiafiltration, although plasma beta2-microglobulin levels remain high with these modalities [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/76-80\">",
"       76-80",
"      </a>",
"      ]. Despite being associated with marked removal, some clinicians feel that hemofiltration and hemodiafiltration do not provide a clear benefit versus that associated with biocompatible high flux hemodialysis performed at high blood flow rates [",
"      <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Dialysis membrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changing the dialysis membrane may be beneficial, but is controversial. Polysulfone membrane dialyzers reprocessed over 24 times were associated with increased Beta2-microglobulin removal and lower predialysis plasma levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted in the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, noncuprophane high flux dialyzers should be utilized in DRA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/5\">",
"     5",
"    </a>",
"    ]. Compared with low flux membranes, superior removal of beta2-microgloublin is associated with high flux membranes in conventional hemodialysis, thereby resulting in decreased beta2-microglobulin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/17\">",
"     17",
"    </a>",
"    ]. In the HEMO study, for example, the low and high flux groups had clearances of beta-2-microglobulin of 3 and 34",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/18\">",
"     18",
"    </a>",
"    ]. There is limited evidence that the use of super-flux membranes may improve beta-2 microglobulin clearance even more than with high flux membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful renal transplantation reduces plasma beta2-microglobulin levels to normal and joint pains usually resolve quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/5,83-85\">",
"     5,83-85",
"    </a>",
"    ]. Over time, there may also be some regression in the amyloid deposits. One study, for example, found regression of articular amyloid deposition in eight of nine patients with DRA as detected by scanning with radiolabeled serum amyloid P component approximately five years after successful renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/85\">",
"     85",
"    </a>",
"    ]. In comparison, bone cysts resolve much more slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that the use of a Beta2-microglobulin column that is available for clinical use in Japan in patients with DRA is associated with increased Beta2-microglobulin removal and better improvement in symptoms versus dialysis alone in patients with DRA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/30/5609/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. However, hypotension and anemia have limited treatment in some patients and the role for this treatment remains undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287938018\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation is the only treatment modality that may slow or halt the progression of DRA. Other than appropriate analgesia, there are no specific medical therapies for DRA. It seems reasonable to use a biocompatible high-flux hemodialysis membrane, although it is not certain that this will prevent progression of DRA or development of new lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287937375\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Among patients with end-stage renal disease, dialysis-related amyloidosis (DRA) is a disorder caused by the inability to clear beta2-microglobulin, resulting in the deposition of amyloid fibrils in bones, joints, and other soft tissues. The incidence of DRA is currently less common than previously reported, a trend that correlates with the increased use of high flux biocompatible dialyzers with enhanced clearance of beta2-microglobulin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The major clinical manifestations of DRA are carpal tunnel syndrome, bone cysts, spondyloarthropathy, pathologic fractures, and swollen, painful joints. The amyloid found in involved tissue is similar to other forms of amyloid in its staining properties with Congo red and in exhibiting apple-green birefringence under polarized light. Plain radiography reveals bone cysts, especially near joints. The diagnosis is based upon the presence of typical clinical features plus characteristic radiographic findings. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical and laboratory manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Radiographic findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Once DRA develops, patients should be dialyzed with biocompatible, high flux hemodialysis membranes, which are the current standard of therapy. In addition, altering the duration, frequency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      type of dialysis treatment may provide some benefit. Renal transplantation is the only modality that appears to slow or halt the progression of DRA. Surgical corrections of diseased bones and joints with modalities such as arthroscopic or open surgery, curettage, and replacement of disease joints may be warranted in cases where debility or pain cannot be controlled with analgesics or other nonsurgical modalities. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/1\">",
"      Fenves AZ, Emmett M, White MG, et al. Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients. Am J Kidney Dis 1986; 7:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/2\">",
"      Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/3\">",
"      Gejyo F, Odani S, Yamada T, et al. Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986; 30:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/4\">",
"      Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998; 9:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/5\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/6\">",
"      Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD: an in-depth review. Adv Ren Replace Ther 2003; 10:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/7\">",
"      Dember LM, Jaber BL. Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial 2006; 19:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/8\">",
"      Jadoul M, Garbar C, No&euml;l H, et al. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 1997; 51:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/9\">",
"      Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006; 70:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/10\">",
"      Gorevic PD, Munoz PC, Casey TT, et al. Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci U S A 1986; 83:7908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/11\">",
"      van Ypersele De Strihou C, Jadoul M, Garbar C. Morphogenesis of joint beta 2-microglobulin amyloid deposits. Nephrol Dial Transplant 2001; 16 Suppl 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/12\">",
"      Yamamoto S, Kazama JJ, Narita I, et al. Recent progress in understanding dialysis-related amyloidosis. Bone 2009; 45 Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/13\">",
"      Zingraff J, Beyne P, Ure&ntilde;a P, et al. Influence of haemodialysis membranes on beta 2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/14\">",
"      Kaiser JP, Hagemann J, von Herrath D, Schaefer K. Different handling of beta 2-microglobulin during hemodialysis and hemofiltration. Nephron 1988; 48:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/15\">",
"      Ullian ME, Hammond WS, Alfrey AC, et al. Beta-2-microglobulin-associated amyloidosis in chronic hemodialysis patients with carpal tunnel syndrome. Medicine (Baltimore) 1989; 68:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/16\">",
"      Goldman M, Lagmiche M, Dhaene M, et al. Adsorption of beta 2-microglobulin on dialysis membranes: comparison of different dialyzers and effects of reuse procedures. Int J Artif Organs 1989; 12:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/17\">",
"      Gejyo, F, Narita, I. Current clinical and pathogenic understanding of beta2-m amyloidosis in long-term haemodialysis patients. Nephrology 2003; (Suppl 8):S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/18\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/19\">",
"      Floege J, Koch KM. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes. Clin Nephrol 1994; 42 Suppl 1:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/20\">",
"      van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/21\">",
"      Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000; 15:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/22\">",
"      Schoels M, Jahn B, Hug F, et al. Stimulation of mononuclear cells by contact with cuprophan membranes: further increase of beta 2-microglobulin synthesis by activated late complement components. Am J Kidney Dis 1993; 21:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/23\">",
"      Zaoui PM, Stone WJ, Hakim RM. Effects of dialysis membranes on beta 2-microglobulin production and cellular expression. Kidney Int 1990; 38:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/24\">",
"      Floege J, Sch&auml;ffer J, Koch KM, Shaldon S. Dialysis related amyloidosis: a disease of chronic retention and inflammation? Kidney Int Suppl 1992; 38:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/25\">",
"      Hakim RM, Wingard RL, Husni L, et al. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/26\">",
"      Traut M, Haufe CC, Eismann U, et al. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study. Blood Purif 2007; 25:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/27\">",
"      Kessler M, Netter P, Azoulay E, et al. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 1992; 31:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/28\">",
"      Brunner FP, Brynger H, Ehrich JH, et al. Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA Registry. Nephrol Dial Transplant 1990; 5:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/29\">",
"      Matsuo K, Ikizler TA, Hoover RL, et al. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Kidney Int 2000; 57:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/30\">",
"      Garc&iacute;a-Garc&iacute;a M, Gouin-Charnet A, Durfort M, et al. Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis. Kidney Int 1999; 55:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/31\">",
"      Cianciolo G, Col&iacute; L, La Manna G, et al. Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach. Int J Artif Organs 2007; 30:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/32\">",
"      Menaa C, Esser E, Sprague SM. Beta2-microglobulin stimulates osteoclast formation. Kidney Int 2008; 73:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/33\">",
"      Fry AC, Singh DK, Chandna SM, Farrington K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 2007; 25:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/34\">",
"      Niwa T, Katsuzaki T, Momoi T, et al. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996; 49:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/35\">",
"      Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/36\">",
"      Hou FF, Miyata T, Boyce J, et al. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int 2001; 59:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/37\">",
"      Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002; 13:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/38\">",
"      Hou FF, Boyce J, Chertow GM, et al. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol 1998; 9:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/39\">",
"      Sprague, SM, Moe, SM. Clinical manifestations and pathogenesis of dialysis-related amyloidosis. Semin Dial 1996; 9:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/40\">",
"      No&euml;l LH, Zingraff J, Bardin T, et al. Tissue distribution of dialysis amyloidosis. Clin Nephrol 1987; 27:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/41\">",
"      Zhou H, Pfeifer U, Linke R. Generalized amyloidosis from beta 2-microglobulin, with caecal perforation after long-term haemodialysis. Virchows Arch A Pathol Anat Histopathol 1991; 419:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/42\">",
"      Sethi D, Hutchison AJ, Cary NR, et al. Macroglossia and amyloidoma of the buttock: evidence of systemic involvement in dialysis amyloid. Nephron 1990; 55:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/43\">",
"      Floege J, Brandis A, Nonnast-Daniel B, et al. Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient. Nephron 1989; 53:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/44\">",
"      Warren DJ, Otieno LS. Carpal tunnel syndrome in patients on intermittent haemodialysis. Postgrad Med J 1975; 51:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/45\">",
"      Kleinman KS, Coburn JW. Amyloid syndromes associated with hemodialysis. Kidney Int 1989; 35:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/46\">",
"      Locatelli F, Marcelli D, Conte F, et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 1999; 55:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/47\">",
"      Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/48\">",
"      Otsubo S, Kimata N, Okutsu I, et al. Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 2009; 24:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/49\">",
"      Nakai S, Iseki K, Tabei K, et al. Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 2001; 38:S212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/50\">",
"      Rabindranath KS, Strippoli GF, Roderick P, et al. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005; 45:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/51\">",
"      Nakazawa R, Hamaguchi K, Hosaka E, et al. Synovial amyloidosis of beta 2-microglobulin type in patients undergoing long-term hemodialysis. Nephron 1986; 44:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/52\">",
"      Fiocchi O, Bedani PL, Orzincolo C, et al. Radiological features of dialysis amyloid spondyloarthropathy. Int J Artif Organs 1989; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/53\">",
"      Allard JC, Artze ME, Porter G, et al. Fatal destructive cervical spondyloarthropathy in two patients on long-term dialysis. Am J Kidney Dis 1992; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/54\">",
"      Chassagne P, Said LA, Le Loet X, et al. Fatal destructive cervical spondyloarthropathy. Am J Kidney Dis 1992; 20:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/55\">",
"      Marcelli C, P&eacute;rennou D, Cyteval C, et al. Amyloidosis-related cauda equina compression in long-term hemodialysis patients. Three case reports. Spine (Phila Pa 1976) 1996; 21:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/56\">",
"      Ikegaya N, Kobayashi S, Hishida A, et al. Colonic dilatation due to dialysis-related amyloidosis. Am J Kidney Dis 1995; 25:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/57\">",
"      Takahashi S, Morita T, Koda Y, et al. Gastrointestinal involvement of dialysis-related amyloidosis. Clin Nephrol 1988; 30:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/58\">",
"      Dulgheru EC, Balos LL, Baer AN. Gastrointestinal complications of beta2-microglobulin amyloidosis: a case report and review of the literature. Arthritis Rheum 2005; 53:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/59\">",
"      Maury CP. beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients. Rheumatol Int 1990; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     Stone, WJ. Beta2-microglobulin-associated amyloidosis of end-stage renal disease in Principles and Practice of Dialysis (Third Edition). Henrich, WL (Ed). 2005, Lippincott, Williams, and Wilkins, Philadelphia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/61\">",
"      Kiss E, Keusch G, Zanetti M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol 2005; 185:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/62\">",
"      Slavotinek JP, Coates PT, McDonald SP, et al. Shoulder appearances at MR imaging in long-term dialysis recipients. Radiology 2000; 217:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/63\">",
"      Cardinal E, Buckwalter KA, Braunstein EM, et al. Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings. AJR Am J Roentgenol 1996; 166:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/64\">",
"      Kay J, Benson CB, Lester S, et al. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 1992; 35:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/65\">",
"      Sommer R, Valen GJ, Ori Y, et al. Sonographic features of dialysis-related amyloidosis of the shoulder. J Ultrasound Med 2000; 19:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/66\">",
"      Jadoul M, Malghem J, Vande Berg B, van Ypersele de Strihou C. Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: a cross-sectional and longitudinal study. Nephrol Dial Transplant 1993; 8:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/67\">",
"      Floege J, Sch&auml;ffer J, Ehlerding G. Beta 2-microglobulin-derived amyloidosis: clinical use of scintigraphy and insights into its pathogenesis. Nephrol Dial Transplant 1993; 8:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/68\">",
"      Tan SY, Baillod R, Brown E, et al. Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999; 14:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/69\">",
"      Sch&auml;ffer J, Burchert W, Floege J, et al. Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. Kidney Int 2000; 58:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/70\">",
"      Nelson SR, Hawkins PN, Richardson S, et al. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet 1991; 338:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/71\">",
"      Takenaka R, Fukatsu A, Matsuo S, et al. Surgical treatment of hemodialysis-related shoulder arthropathy. Clin Nephrol 1992; 38:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/72\">",
"      Naito M, Ogata K, Shiota E, Oyama M. Amyloid bone cysts of the femoral neck. Impending fractures treated by curettage and bone grafting. J Bone Joint Surg Br 1994; 76:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/73\">",
"      Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial 2005; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/74\">",
"      Skroeder NR, Jacobson SH, Holmquist B, et al. Beta 2-microglobulin generation and removal in long slow and short fast hemodialysis. Am J Kidney Dis 1993; 21:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/75\">",
"      Raj DS, Ouwendyk M, Francoeur R, Pierratos A. beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/76\">",
"      Van Ypersele de Strihou, C, et al. Dialysis amyloidosis. Adv Nephrol 1988; 17:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/77\">",
"      Lornoy W, Becaus I, Billiouw JM, et al. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 2000; 15 Suppl 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/78\">",
"      Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/79\">",
"      Canaud B, Assounga A, Kerr P, et al. Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992; 7:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/80\">",
"      Penne EL, van der Weerd NC, Blankestijn PJ, et al. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 2010; 5:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/81\">",
"      Diaz RJ, Washburn S, Cauble L, et al. The effect of dialyzer reprocessing on performance and beta 2-microglobulin removal using polysulfone membranes. Am J Kidney Dis 1993; 21:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/82\">",
"      Pellicano R, Polkinghorne KR, Kerr PG. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial. Am J Kidney Dis 2008; 52:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/83\">",
"      Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/84\">",
"      Mourad G, Argil&eacute;s A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996; 7:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/85\">",
"      Tan SY, Irish A, Winearls CG, et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996; 50:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/86\">",
"      Jadoul M, Malghem J, Pirson Y, et al. Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clin Nephrol 1989; 32:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/87\">",
"      Gejyo F, Kawaguchi Y, Hara S, et al. Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. Artif Organs 2004; 28:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/88\">",
"      Abe T, Uchita K, Orita H, et al. Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 2003; 64:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/30/5609/abstract/89\">",
"      Kutsuki H. beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta 2005; 1753:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1983 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5609=[""].join("\n");
var outline_f5_30_5609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H287937375\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clearance of beta2-microglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intradialytic beta2-microglobulin production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of reactive inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Modification of beta2-microglobulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL AND LABORATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Scapulohumeral periarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effusive arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Spondyloarthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other sites of involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Beta2-microglobulin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tissue histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgery and analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Increased clearance of beta2-microglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Duration, frequency, and type of dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Dialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H287938018\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287937375\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1983|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/39/13936\" title=\"diagnostic image 1\">",
"      Radiograph of pt with dialysis related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1983|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/62/35821\" title=\"figure 1\">",
"      Dialysis amyloidosis in elderly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2643?source=related_link\">",
"      Uremic mononeuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_30_5610="Nocardia 1";
var content_f5_30_5610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nocardia pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Nocardia organisms with typical characteristic Chinese letter pattern. B) GMS stain with Nocardia organisms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cagle PT, MD. Color Atlas and Text of Pulmonary Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5610=[""].join("\n");
var outline_f5_30_5610=null;
var title_f5_30_5611="Clinical features of tonic pupil";
var content_f5_30_5611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of the tonic pupil",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Poor pupillary light reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental palsy of the sphincter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tonic pupillary near response with light-near dissociation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholinergic supersensitivity of the denervated muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accommodation paresis (that tends to recover)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induced astigmatism at near and tonicity of accommodation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occasional \"ciliary cramp\" (accommodative spasm) with near work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occasionally regional corneal anesthesia (trigeminal fibers in ciliary ganglion damaged)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thompson, HS. Adie's syndrome: Some new observations. Trans Am Ophthalmol Soc 1977; 75:587. Copyright &copy; 1977 American Ophtalmalogic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5611=[""].join("\n");
var outline_f5_30_5611=null;
var title_f5_30_5612="Rx malignant pleural effusion";
var content_f5_30_5612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of malignant and paramalignant pleural effusions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Option",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observation",
"       </td>",
"       <td>",
"        For asymptomatic effusions; most will progress and require therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Therapeutic thoracentesis",
"       </td>",
"       <td>",
"        Prompt relief of dyspnea; most effusions recur unless underlying tumor responds to chemo- or radiotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest catheter drainage only",
"       </td>",
"       <td>",
"        Most effusions will recur after catheter removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest catheter drainage with chemical pleurodesis (eg, talc slurry)",
"       </td>",
"       <td>",
"        Variable response rate with&nbsp;60 to&nbsp;90 percent of patients responding to talc pleurodesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracoscopy with talc insufflation",
"       </td>",
"       <td>",
"        Control of effusion with similar frequency as chest catheter drainage with talc pleurodesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long-term indwelling pleural catheter",
"       </td>",
"       <td>",
"        Control of effusion and improved symptoms in most patients. Some patients may experience pleurodesis after&nbsp;two weeks (median 11 weeks)&nbsp;of catheter drainage, which allows catheter removal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural abrasion or pleurectomy",
"       </td>",
"       <td>",
"        Requires thoracoscopy or thoracotomy. Effectively controls effusions in nearly all patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleuroperitoneal shunt",
"       </td>",
"       <td>",
"        When other options have failed or are not indicated; may be useful for chylothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy",
"       </td>",
"       <td>",
"        May be effective in some tumor types, such as breast cancer, lymphoma, and small cell lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiotherapy",
"       </td>",
"       <td>",
"        Mediastinal radiation therapy may be effective in lymphoma and lymphomatous chylothorax",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5612=[""].join("\n");
var outline_f5_30_5612=null;
var title_f5_30_5613="Composition ORS beverages";
var content_f5_30_5613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of oral rehydration solutions (ORS) and commonly used beverages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Carbohydrate (g/L)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        mEq/L",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Osmolarity (mOSM/kg H2O)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Sodium",
"       </td>",
"       <td class=\"subtitle2\">",
"        Potassium",
"       </td>",
"       <td class=\"subtitle2\">",
"        Base (HCO3-)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Oral rehydration solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CeraLyte&reg;",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        235",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enfalyte&reg;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pedialyte&reg;",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        250",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rehydralyte&reg;",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        WHO (1975)",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        WHO (2002)",
"       </td>",
"       <td>",
"        13.5",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        245",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Commonly Used Beverages (not appropriate for repletion therapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple juice",
"       </td>",
"       <td>",
"        100-150",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chicken broth",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        450",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colas",
"       </td>",
"       <td>",
"        100-150",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        550",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gatorade&reg;",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        330",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginger Ale",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"       <td>",
"        565",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tea",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5613=[""].join("\n");
var outline_f5_30_5613=null;
var title_f5_30_5614="Rx acute variceal bleed";
var content_f5_30_5614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management of acute variceal hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are only general guidelines and appropriate therapy should be based on the patient's individual circumstances and the expertise available.",
"    <div class=\"footnotes\">",
"     EST: endoscopic sclerotherapy; EVL: endoscopic variceal band ligation.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Sanyal A, et al, Semin Liver Dis 1993; 13:4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5614=[""].join("\n");
var outline_f5_30_5614=null;
var title_f5_30_5615="Womens health initiative risk of heart disease";
var content_f5_30_5615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76930%7EENDO%2F62591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76930%7EENDO%2F62591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Women's Health Initiative: Risk of heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of cumulative hazard rates of CHD. In the Women's Health Initiative, combined estrogen-progestin therapy was associated with a significant increase in coronary events. CHD included nonfatal myocardial infarction and death due to CHD. The overall hazard ratio for CHD was 1.24 (nominal 95% CI, 1.00-1.54).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Estrogen therapy not beneficial for secondary prevention of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the HERS-II trial on the incidence of coronary heart disease events (death or nonfatal myocardial infarction) in 2763 postmenopausal women with a prior history of myocardial infarction or interventional procedure who were treated with combined hormone replacement therapy of placebo. There was no difference between the two groups. The curves are truncated at year 7 when less than half of the cohort remained in follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Grady D, Herrington D, Bittner V, et al. JAMA 2002; 288:49.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_30_5615=[""].join("\n");
var outline_f5_30_5615=null;
